


EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2544	((544/330,332) or (514/275)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/11/21 23:01

NPL Search Notes		Results
6.	TITLE-ABSTR-KEY(IgE-mediated or immunoglobulin synthesis) and TITLE-ABSTR-KEY (transplant rejection) [All Sources(- All Sciences -)]	2
5.	TITLE-ABSTR-KEY(IgE-mediated or immunoglobulin synthesis) and TITLE-ABSTR-KEY (gastrointestinal) [All Sources(- All Sciences -)]	172
4.	TITLE-ABSTR-KEY(IgE-mediated or immunoglobulin synthesis) and TITLE-ABSTR-KEY (autoimmune) [All Sources(- All Sciences -)]	81
3.	(TITLE-ABSTR-KEY(IgE-mediated)) AND (TITLE-ABSTR-KEY(immunoglobulin synthesis)) [All Sources(- All Sciences -)]	1
2.	TITLE-ABSTR-KEY(IgE-mediated) [All Sources(- All Sciences -)]	4083
1.	TITLE-ABSTR-KEY(immunoglobulin synthesis) [All Sources(- All Sciences -)]	1304

Copyright © 2006 Elsevier B.V. All rights reserved.
ScienceDirect® is a registered trademark of Elsevier B.V.



chain nodes :

19 22 23 26

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

5-19 9-19 22-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17
17-18

exact/norm bonds :

5-19 9-19 22-23

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17
17-18

isolated ring systems :

containing 1 : 7 : 13 :

G1:Cl,Br,F,I,X,[*1]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS20:Atom 22:CLASS23:CLASS26:CLASS
27:Atom

Generic attributes :



22:

Saturation : Saturated

Number of Carbon Atoms : less than 7

=>

Uploading C:\Program Files\Stnexp\Queries\10501445.str



```

chain nodes :
19 22 23 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
5-19 9-19 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
5-19 9-19 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 :
```

G1:Cl,Br,F,I,X,[*1]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:Atom 22:CLASS 23:CLASS 26:CLASS 27:Atom
Generic attributes :
22:
```

Saturation : Saturated
Number of Carbon Atoms : less than 7

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:11:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2235 TO ITERATE

89.5% PROCESSED 2000 ITERATIONS

9 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 41865 TO 47535

PROJECTED ANSWERS: 11 TO 391

L2 9 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 17:12:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 46908 TO ITERATE

100.0% PROCESSED 46908 ITERATIONS

378 ANSWERS

SEARCH TIME: 00.00.03

L3 378 SEA SSS FUL L1

=> => s l3

L4 47 L3

=> d l4 1-47 bib,ab,hitstr

L4 ANSWER 1 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:542661 CAPLUS
 DN 145:46082
 TI Preparation of substituted heterocycles for treating HGF mediated diseases
 IN Kim, Tae-Seong; Bellon, Steven; Booker, Shon; D'Angelo, Noel; Dominguez, Celia; Fellows, Ingrid; Lee, Matthew; Liu, Longbin; Rainbeau, Elizabeth; Siegmund, Aaron C.; Tasker, Andrew; Xi, Ning; Cheng, Yuan
 PA Amgen Inc., USA
 SO PCT Int. Appl., 228 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060318	A2	20060608	WO 2005-US42935	20051129
WO 2006060318	A3	20060720		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006252777	A1	20061109	US 2005-289659	20051129
PRAI US 2004-632271P	P	20041130		

OS MARPAT 145:46082

AB The title compds. R1XWAYR [I; R = (un)substituted aryl, heterocyclyl, cycloalkyl, etc.; R1 = II (wherein ring T = Ph, 5-6 membered heteroaryl; Z = N or CH; R10 = alkoxy, haloalkoxy, arylalkoxy, etc.); W = (un)substituted aryl, 5-6 membered heteroaryl; A = (un)substituted 5-7 membered N-containing heterocyclyl; X = O, S, NR2, CR3R4; Y = a bond, CO, CONH, etc.; R2 = H, alkyl, haloalkyl, etc.; R3, R4 = H, alkyl, aryl, etc.] which are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from 2-benzyl-3H-pyrimidin-4-one, was given. Compds. I showed inhibition of c-Met kinase at doses less than 2 μ M. The invention encompasses novel compds. I, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes.

IT 890020-03-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted heterocycles for treating HGF mediated diseases.)

RN 890020-03-8 CAPLUS

CN 4(1H)-Pyrimidinone, 5-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]-2-[(4-fluoro-2-methylphenyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 2 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:440209 CAPLUS

DN 144:468191

TI Preparation of phenylpyrimidinecarboxamides as modulators of voltage-gated sodium and calcium channels

IN Martinborough, Esther; Zimmermann, Nicole; Perni, Robert; Arnost, Michael; Bandarage, Upul; Maltais, Francois; Bemis, Guy

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 166 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006050476	A2	20060511	WO 2005-US39881	20051103
	WO 2006050476	A3	20061019		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	US 2006160817	A1	20060720	US 2005-266142	20051103
PRAI	US 2004-624716P	P	20041103		
	US 2004-624718P	P	20041103		
	US 2004-624800P	P	20041103		

OS MARPAT 144:468191

AB Title compds. I [wherein X = halo, cyano, Me, etc.; n = 1-4; R1, R2 = H, alkyl, cycloalkyl, etc.; R3, R4 = H, alkyl, heterocyclyl, etc.; Y = H or alkyl] and pharmaceutically acceptable salts thereof were prepared as ion channel modulators, especially as voltage-gated sodium and calcium channel inhibitors. For instance, II was synthesized in multiple steps and showed inhibitory activity for CaV 2.2, Nav 1.3 and Nav 1.8 with IC50 values of < 10.0 μ M. I and their pharmaceutical compns. are useful for the treatment of various diseases.


IT 886196-10-7P 886196-14-1P 886196-39-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of phenylpyrimidinecarboxamides as inhibitors of voltage-gated sodium and calcium channels)


RN 886196-10-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-4-(2-fluorophenyl)-N-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 886196-14-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-[(4-fluorophenyl)amino]-N-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 886196-39-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)amino]-4-(2-fluorophenyl)-N-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:340006 CAPLUS
 DN 144:390933
 TI Preparation of anilinopyrimidines as IKK kinase inhibitors
 IN Sum, Fuk-Wah; Powell, Dennis William; Zhang, Yixian; Chen, Lijing;
 Kincaid, Scott Lee; Jennings, Lee Dalton; Hu, Yongbo; Gilbert, Adam
 Matthew; Bursavich, Matthew Gregory
 PA Wyeth, John, and Brother Ltd., USA
 SO U.S. Pat. Appl. Publ., 55 pp.
 CODEN: USXXCO

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006079543	A1	20060413	US 2005-248495	20051013
	WO 2006044457	A1	20060427	WO 2005-US36674	20051013
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-617668P P 20041013

OS MARPAT 144:390933

AB Title compds. I [wherein R1, R4 = H; R2 = (un)substituted amino, guanidiny, ureido, etc.; R3 = H, (un)substituted Ph, certain heteroaryl, etc.; R5 = H, alkyl, alkylsulfonyl, etc.; R6 = H, halo, (un)substituted Ph, etc.] and salts, solvates or hydrates thereof were prepared as kinase inhibitors, especially IKK kinase inhibitors. For instance, condensation of 2-acetyl-5-chlorothiophene with DMF di-Me acetal followed by cyclization with a guanidine, which was obtained by treatment of sulfanilamide with 1H-pyrazole-1-carboximidamide hydrochloride, gave 2-pyrimidinamine II. Exemplary I gave a pos. or slightly pos. result in the western anal. of IKK α . Therefore, I and their pharmaceutical compns. are useful for the treatment of diseases associated with NF- κ B activation, such as inflammation, tumor and ischemic conditions.

IT 882875-57-2P 882875-63-0P 882875-64-1P

882875-65-2P 882875-66-3P 882875-68-5P


882875-69-6P 882875-70-9P 882875-71-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of anilinopyrimidines as IKK kinase inhibitors)


RN 882875-57-2 CAPLUS

CN Benzenesulfonamide, 2-chloro-5-[[4-(3-fluoro-4-methoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 882875-63-0 CAPLUS

CN Benzenesulfonamide, N-[3-(dimethylamino)propyl]-4-[[4-(3-fluoro-4-methoxyphenyl)-2-pyrimidinyl]amino]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 882875-64-1 CAPLUS

CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-[[4-(3-fluoro-4-methoxyphenyl)-2-pyrimidinyl]amino]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 882875-65-2 CAPLUS

CN Benzenesulfonamide, N-[3-(dimethylamino)propyl]-4-[[4-(4-methoxyphenyl)-2-pyrimidinyl]amino]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 882875-66-3 CAPLUS

CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-[[4-(4-methoxyphenyl)-2-pyrimidinyl]amino]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 882875-68-5 CAPLUS

CN Benzenesulfonamide, 2-chloro-N-[2-(dimethylamino)ethyl]-4-[[4-(3-fluoro-4-methoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 882875-69-6 CAPLUS

CN Benzenesulfonamide, 2-chloro-N-[2-(dimethylamino)ethyl]-4-[[4-(4-methoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 882875-70-9 CAPLUS

CN Benzenesulfonamide, 2-chloro-N-[3-(dimethylamino)propyl]-4-[[4-(3-fluoro-4-methoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 882875-71-0 CAPLUS

CN Benzenesulfonamide, 2-chloro-N-[3-(dimethylamino)propyl]-4-[[4-(4-methoxyphenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:301346 CAPLUS
 DN 144:350708
 TI Novel pyrimidine compounds, process for their preparation, pharmaceutical compositions, and their use as antiinflammatory, cytotoxic, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases
 IN Kalleda, Srinivas; Padakanti, Srinivas; Kumar Swamy, Nalivela; Yeleswarapu, Koteswar Rao; Alexander, Christopher W.; Khanna, Ish Kumar; Iqbal, Javed; Pillarisetti, Sivaram; Pal, Manojit; Barange, Deepak
 PA Reddy US Therapeutics, Inc., USA
 SO PCT Int. Appl., 336 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006034473	A2	20060330	WO 2005-US34243	20050923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006084644	A1	20060420	US 2005-234257	20050923
US 2006084645	A1	20060420	US 2005-234695	20050923
PRAI US 2004-612374P	P	20040923		

OS MARPAT 144:350708


AB The invention provides heterocyclic compds., particularly substituted pyrimidines of formula I, methods and compns. for making and using these heterocyclic compds., and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan. Compds. of formula I wherein R1, R2 and R4 are independently (un)substituted (hetero)aryl or (un)substituted heterocyclyl; and their pharmaceutically acceptable salts, prodrugs, diastereoisomeric mixts., enantiomers, tautomers, and racemic mixts. thereof are claimed in this invention. Example compound II was prepared by acylation of 4-methoxyacetophenone with di-Et carbonate; the resulting Et 4-methoxybenzoylacetate underwent cyclization with guanidine carbonate to give 2-amino-6-(4-methoxyphenyl)pyrimidin-4-ol, which was converted to 4-chloro-6-(methoxyphenyl)pyrimidin-2-ylamine, which underwent amination with 3-chloro-4-methoxyaniline to give compound II. The invention compds. were evaluated for their antiinflammatory, proliferative, cardiovascular, and immunosuppressive activity (no data).

IT 881193-46-0P 881193-55-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)


RN 881193-46-0 CAPLUS

CN 4-Piperidinol, 1-[2-[(3-chloro-4-methoxyphenyl)amino]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 881193-55-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluoro-4-methoxyphenyl)-4-phenyl-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




IT 881193-14-2P 881193-24-4P 881193-25-5P
 881193-26-6P 881193-27-7P 881193-28-8P
 881193-29-9P 881193-30-2P 881193-31-3P
 881193-32-4P 881193-33-5P 881193-34-6P
 881193-50-6P 881193-51-7P 881193-53-9P
 881193-56-2P 881193-57-3P 881193-59-5P
 881193-60-8P 881193-61-9P 881193-64-2P
 881193-65-3P 881193-66-4P 881193-67-5P
 881194-05-4P 881194-06-5P 881194-08-7P
 881194-24-7P 881194-27-0P 881194-29-2P
 881194-30-5P 881194-31-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyrimidine compds. and their use as
 antiinflammatory, proliferative, rheumatic, immunosuppressive and
 cardiovascular agents for treatment of diseases)


RN 881193-14-2 CAPLUS

CN 2,4-Pyrimidinediamine, N,N'-bis(3-chloro-4-methoxyphenyl)-6-phenyl- (9CI)
 (CA INDEX NAME)




RN 881193-24-4 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(3-chloro-4-methoxyphenyl)-N4-methyl-6-phenyl-
(9CI) (CA INDEX NAME)




RN 881193-25-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(3-chloro-4-methoxyphenyl)-N4-(1-methylethyl)-6-
phenyl- (9CI) (CA INDEX NAME)



RN 881193-26-6 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chloro-4-methoxyphenyl)-N4-cycloheptyl-6-
phenyl- (9CI) (CA INDEX NAME)



RN 881193-27-7 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chloro-4-methoxyphenyl)-6-phenyl-N4-

(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 881193-28-8 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(3-chloro-4-methoxyphenyl)amino]-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 881193-29-9 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(3-chloro-4-methoxyphenyl)amino]-6-phenyl- (9CI) (CA INDEX NAME)




RN 881193-30-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-ethoxy-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 881193-31-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-methoxyphenyl)-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 881193-32-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-methoxyphenyl)-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 881193-33-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-methoxyphenyl)-6-[(4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 881193-34-6 CAPLUS

CN Acetic acid, [[2-[(3-chloro-4-methoxyphenyl)amino]-6-(4-methoxyphenyl)-4-pyrimidinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 881193-50-6 CAPLUS

CN 4-Piperidinol, 1-[2-[(3-chloro-4-hydroxyphenyl)amino]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 881193-51-7 CAPLUS

CN 4-Piperidinol, 1-[2-[(3-fluoro-4-methoxyphenyl)amino]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 881193-53-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-phenyl-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 881193-56-2 CAPLUS

CN Phenol, 2-chloro-4-[[4-phenyl-6-(4-thiomorpholinyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 881193-57-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-morpholinyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 881193-59-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluoro-4-methoxyphenyl)-4-(4-morpholinyl)-6-phenyl-
(9CI) (CA INDEX NAME)




RN 881193-60-8 CAPLUS

CN Phenol, 2-chloro-4-[[4-(4-morpholinyl)-6-phenyl-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 881193-61-9 CAPLUS

CN 4-Piperidinol, 1-[6-phenyl-2-[[3-(trifluoromethyl)phenyl]amino]-4-
pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 881193-64-2 CAPLUS


CN 2-Pyrimidinamine, 4-(4-fluorophenyl)-6-(4-morpholinyl)-N-[3-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 881193-65-3 CAPLUS
 CN 2-Pyrimidinamine, N,4-bis(4-fluorophenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 881193-66-4 CAPLUS
 CN 4-Piperidinol, 1-[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-6-phenyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 881193-67-5 CAPLUS
 CN 2-Pyrimidinamine, 4-(4-morpholinyl)-6-phenyl-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 881194-05-4 CAPLUS
 CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-phenyl-6-(phenylethynyl)- (9CI) (CA INDEX NAME)




RN 881194-06-5 CAPLUS

CN Ethanol, 2-[[2-[(3-chloro-4-methoxyphenyl)amino]-6-phenyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 881194-08-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-phenyl-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 881194-24-7 CAPLUS

CN Butanedioic acid, mono[1-[2-[(3-chloro-4-methoxyphenyl)amino]-6-phenyl-4-pyrimidinyl]-4-piperidinyl] ester (9CI) (CA INDEX NAME)




RN 881194-27-0 CAPLUS

CN Cyclohexanol, 4-[[2-[(3-chloro-4-methoxyphenyl)amino]-6-phenyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 881194-29-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-ethyl-1-piperazinyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 881194-30-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 881194-31-6 CAPLUS

CN 2-Pyrimidinamine, 4-(1,1-dioxido-4-thiomorpholinyl)-N-(3-fluoro-4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




IT 881195-06-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)

RN 881195-06-8 CAPLUS

CN 2-Pyrimidinamine, 4-chloro-N-(3-chloro-4-methoxyphenyl)-6-phenyl- (9CI)
(CA INDEX NAME)



L4 ANSWER 5 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:180156 CAPLUS

DN 144:390868

TI Synthesis of analogs of the phenylamino-pyrimidine type protein kinase C inhibitor CGP 60474 utilizing a Negishi cross-coupling strategy

AU Stanetty, Peter; Roehrling, Juergen; Schnuerch, Michael; Mihovilovic, Marko D.

CS Institute of Applied Synthetic Chemistry, Vienna University of Technology, Vienna, A-1060, Austria

SO Tetrahedron (2006), 62(10), 2380-2387

CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier B.V.

DT Journal

LA English

AB Analogs of 3-[[4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-1-propanol (CGP 60474) were synthesized as useful models for the evaluation of structure-activity relationships of phenylamino-pyrimidine-type protein kinase C inhibitors. The approach involved Pd-assisted cross-coupling as the key step. Negishi-type coupling was performed both with free amino functionalities and Boc-protected amines present and showed that the protection-cross-coupling-deprotection sequence leads to significantly higher yields. The results of biol. screening of the title compds. showed no improved fungicidal activity over CGP 60474 and will be reported elsewhere.


IT 883199-29-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of [[[chlorophenyl]amino]pyrimidinyl]pyridinyl]amino]propanol (CGP 60474) analogs and derivs. using (chlorophenyl)[(acylamino)phenyl]pyrimidinamine as intermediate and Negishi cross-coupling as key synthetic step)

RN 883199-29-9 CAPLUS

CN Propanoic acid, 3-[[3-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 883199-16-4P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of [[[chlorophenyl]amino]pyrimidinyl]pyridinyl]amino]propanol (CGP 60474) analogs and derivs. using Negishi cross-coupling as key synthetic step)

RN 883199-16-4 CAPLUS


CN 1-Propanol, 3-[[3-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]phenyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1174303 CAPLUS
 DN 144:22887
 TI Novel synthesis of N-phenyl-2-aminopyrimidine derivatives under solvent-free conditions.
 AU Kidemet, Davor; Elenkov, Ivaylo; Prgomet, Vesna
 CS Pliva Research Institute Ltd., Zagreb, 10000, Croatia
 SO Synlett (2005), (16), 2531-2533
 CODEN: SYNLES; ISSN: 0936-5214
 PB Georg Thieme Verlag
 DT Journal
 LA English
 OS CASREACT 144:22887
 AB An efficient method for the solvent-free synthesis of N-phenyl-2-aminopyrimidines was developed through cyclocondensation of N-phenylguanidine with enaminone in the presence of DBU. The procedure is exptl. simple with very short reaction times and good yields. According to this procedure a variety of N-phenyl-2-aminopyrimidines were synthesized.
 IT 870002-52-1P 870002-53-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of N-phenyl-2-aminopyrimidine derivs. by cyclocondensation of N-phenylguanidine with enaminone using DBU base under solvent-free conditions)
 RN 870002-52-1 CAPLUS
 CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 870002-53-2 CAPLUS
 CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 7 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1123789 CAPLUS
 DN 143:427366
 TI Compositions and methods for treatment of inflammatory conditions using
 steroid sparing agents
 IN Lieberburg, Ivan
 PA Elan Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 782 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005097162	A2	20051020	WO 2005-US11307	20050401
	WO 2005097162	A3	20060406		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005231467	A1	20051020	AU 2005-231467	20050401
	US 2006004019	A1	20060105	US 2005-95822	20050401
PRAI	US 2004-558121P	P	20040401		
	WO 2005-US11307	W	20050401		
OS	MARPAT 143:427366				
AB	This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft vs. host disease (GVHD), host vs. graft disease, and various spondyloarthropathies, comprising administering a steroid sparing Ig that modulates $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins, or an amino acid-based small (heterocyclic) mol. to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions, including an immunosuppressant, an anti-TNF compound, and a 5-ASA compound. For example, a steroid sparing agent was prepared by converting L-tyrosine tert-Bu ester to L-4-(N,N-dimethylcarbamyloxy)-phenylalanine tert-Bu ester and coupling it to 4,6-dichloro-5-piperidin-1-yl-pyrimidine to give N-(5-piperidin-yl)pyrimidin-4-yl-L-4-(N,N-dimethylcarbamyloxy)phenylalanine. Also, Natalizumab, a humanized monoclonal IgG4 antibody to $\alpha 4$ integrin, was evaluated in subjects with Chron's disease. Monthly administration of Natalizumab for 6 mo was well tolerated and enabled subjects to be successfully withdrawn from steroids.				
IT	285139-65-3P RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of steroid sparing agents for treatment of inflammatory conditions)				
RN	285139-65-3 CAPLUS				
CN	L-Tyrosine, N-[2-[(4-chlorophenyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L4 ANSWER 8 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1024910 CAPLUS
DN 143:381701
TI Diamino-C,N-diarylpyridine positional isomers as inhibitors of
lysophosphatidic acid acyltransferase- β
AU Hong, Feng; Hollenback, David; Singer, Jack W.; Klein, Peter
CS Cell Therapeutics, Inc., Seattle, WA, 98119, USA
SO Bioorganic & Medicinal Chemistry Letters (2005) 15(21), 4703-4707
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 143:381701
AB 2,6-Diamino-4,N-diarylpyridines were identified as potent, isoform
selective inhibitors of the enzymic activity of lysophosphatidic acid
acyltransferase- β (LPAAT- β).
IT 710334-91-1
RL: PAC (Pharmacological activity); BIOL (Biological study)
(diamino-C,N-diarylpyridine isomers preparation and inhibition of
LPAAT- β)
RN 710334-91-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N2-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:371231 CAPLUS
 DN 142:430290
 TI Preparation of 5-arylpyrimidine derivatives as inhibitors of mixed lymphocyte reaction
 IN Tsuruoka, Hiroyuki; Ueda, Kiyono; Sugano, Yuichi; Tatsuta, Toru
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 124 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037802	A1	20050428	WO 2004-JP15653	20041015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005139170	A2	20050602	JP 2004-297133	20041012
PRAI JP 2003-356170	A	20031016		

OS MARPAT 142:430290

AB The title compds. I [R1 and R3 each is lower alkyl; R2 and R4 each is aryl, etc.; R5 is aryl, etc.; R6 is hydrogen; and R7 is aryl, etc.] are prepared Thus, 1-(4-pyridyl)-1-ethanone N-(2-anilino-5-phenyl-6-[2-[1-(4-pyridyl)ethylidene]hydrazono]-4-pyrimidinyl)hydrazone was prepared in 2 steps from 4,6-dihydroxy-5-phenyl-2-phenylaminopyrimidine. Compds. of this invention in vitro showed IC50 values of 0.25 ng/mL to 0.53 ng/mL against the mixed lymphocyte reaction. Formulations are given.


IT 850706-89-7P 850707-28-7P 850707-29-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-arylpyrimidine derivs. as inhibitors of mixed lymphocyte reaction)


RN 850706-89-7 CAPLUS

CN Benzenesulfonamide, 4,4'-[[2-[(5-fluoro-2-methylphenyl)amino]-5-phenyl-4,6-pyrimidinediyl]bis(2-hydrazinyl-1-ylideneethylidene)]bis[N-methyl- (9CI) (CA INDEX NAME)




RN 850707-28-7 CAPLUS

CN Benzenesulfonamide, 4-[1-[2-[(4-fluorophenyl)amino]-5-phenyl-6-[[1-(4-pyridinyl)ethylidene]hydrazino]-4-pyrimidinyl]hydrazono]ethyl]-N-methyl-
(9CI) (CA INDEX NAME)



RN 850707-29-8 CAPLUS

CN Benzenesulfonamide, 4-[1-[2-[(2-fluorophenyl)amino]-5-phenyl-6-[[1-(4-pyridinyl)ethylidene]hydrazino]-4-pyrimidinyl]hydrazono]ethyl]-N-methyl-
(9CI) (CA INDEX NAME)



IT 850707-80-1P 850707-81-2P 850708-07-5P

850708-08-6P 850708-09-7P 850708-10-0P

850708-11-1P 850708-12-2P 850708-13-3P


850708-14-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 5-arylpyrimidine derivs. as inhibitors of mixed lymphocyte reaction)


RN 850707-80-1 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-6-hydroxy-5-phenyl- (9CI) (CA INDEX NAME)




RN 850707-81-2 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-6-hydrazino-5-phenyl-, hydrazone (9CI) (CA INDEX NAME)




RN 850708-07-5 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(4-fluorophenyl)amino]-6-hydroxy-5-phenyl- (9CI) (CA INDEX NAME)




RN 850708-08-6 CAPLUS

CN 2-Pyrimidinamine, 4,6-dichloro-N-(4-fluorophenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 850708-09-7 CAPLUS

CN 4(1H)-Pyrimidinone, 6-chloro-2-[(4-fluorophenyl)amino]-5-phenyl-,
hydrazone (9CI) (CA INDEX NAME)




RN 850708-10-0 CAPLUS

CN Benzenesulfonamide, 4-[1-[[6-chloro-2-[(4-fluorophenyl)amino]-5-phenyl-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 850708-11-1 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(2-fluorophenyl)amino]-6-hydroxy-5-phenyl- (9CI)
(CA INDEX NAME)




RN 850708-12-2 CAPLUS

CN 2-Pyrimidinamine, 4,6-dichloro-N-(2-fluorophenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 850708-13-3 CAPLUS

CN 4(1H)-Pyrimidinone, 6-chloro-2-[(2-fluorophenyl)amino]-5-phenyl-, hydrazone (9CI) (CA INDEX NAME)



RN 850708-14-4 CAPLUS

CN Benzenesulfonamide, 4-[1-[[6-chloro-2-[(2-fluorophenyl)amino]-5-phenyl-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:371230 CAPLUS
 DN 142:430289
 TI Preparation of pyrimidine compounds as mixed lymphocyte reaction (MLR) inhibitors
 IN Tsuruoka, Hiroyuki; Matsuda, Akihisa; Sugano, Yuichi; Tatsuta, Toru
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 350 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037801	A1	20050428	WO 2004-JP15955	20041021
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2005145956	A2	20050609	JP 2004-302344	20041018
PRAI	JP 2003-360967	A	20031021		

OS MARPAT 142:430289

AB Disclosed is a pyrimidine derivative with excellent MLR inhibitory effect or a pharmacol. acceptable salt thereof. Pyrimidine derivs. represented by the general formula (I) or pharmacol. acceptable salts thereof [R1 = lower alkyl; R2 = each (un)substituted aryl or heterocyclyl; A = NH, O; R3 = H, lower alkyl, heterocyclyl, aryl, heterocyclyl, -NHR6 (wherein R6 = lower alkyl, cycloalkyl-lower alkyl, aralkyl, each (un)substituted cycloalkyl, aryl, or heterocyclyl); R4 = H, lower alkyl, lower alkoxy, cycloalkyl-lower alkyl, aralkyl, each (un)substituted aryl or heterocyclyl; provided that R3 = R4 ≠ H; R5 = H, halo, lower alkyl, cycloalkyl, (un)substituted heterocyclyl, NR7R8, OR7 (wherein R7, R8 = H, cycloalkyl, (un)substituted aryl or lower alkyl)] are prepared These compds. exhibit excellent MLR inhibitory effect and are useful as inhibitors of allograft rejection in bone marrow and organ transplant or for the prevention and/or treatment of inflammatory diseases, organ-specific or organ-nonspecific autoimmune diseases, allergic diseases, chronic rheumatism, multiple sclerosis, inflammatory bowel disease, diabetes, glomerulonephritis, primary biliary liver cirrhosis, chronic active hepatitis, pernicious anemia, chronic thyroiditis, atrophic gastritis, myasthenia gravis, psoriasis, Sjogren's syndrome, systemic lupus erythematosus, rhinitis, asthma, or atopic dermatitis. Thus, 0.1 mmol 4-hydrazino-2,6-bis(2-methoxyphenylamino)pyrimidine was dissolved in 1 mL ethanol, treated with 0.1 mmol 4-acetylpyridine, and stirred for 18 h to give 4-[N'-[1-(pyridin-4-yl)ethylidene]hydrazino]-2,6-bis(2-methoxyphenylamino)pyrimidine. N-methyl-4-[1-[[5-phenyl-2-phenylamino-6-[4-(pyridin-4-yl)pyrazol-1-yl]pyrimidin-4-yl]hydrazono]ethyl]benzenesulfonamide (II) inhibited MLR in human peripheral hemolymphocyte offered from two healthy people with IC50 of 1.0 ng/mL.

IT 850756-40-0P 850756-61-5P 850756-70-6P
 850757-41-4P 850757-42-5P 850757-43-6P

850757-58-3P 850757-62-9P 850758-21-3P


850758-22-4P 850758-23-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine compds. as mixed lymphocyte reaction (MLR) inhibitors)


RN 850756-40-0 CAPLUS

CN Benzenesulfonamide, 4-[1-[[2-[(5-fluoro-2-methylphenyl)amino]-5-phenyl-6-[4-(4-pyridinyl)-1H-pyrazol-1-yl]-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 850756-61-5 CAPLUS

CN Benzenesulfonamide, 4-[1-[[2-[(2-fluorophenyl)amino]-5-phenyl-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 850756-70-6 CAPLUS

CN Benzenesulfonamide, 4-[1-[[2-[(5-fluoro-2-methylphenyl)amino]-5-phenyl-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 850757-41-4 CAPLUS

CN Benzenesulfonamide, 4-[1-[[2-[(5-fluoro-2-methylphenyl)amino]-5-phenyl-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]hydrazono]ethyl]-N-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)



RN 850757-42-5 CAPLUS


CN Benzenesulfonamide, 4-[1-[[2-[(5-fluoro-2-methylphenyl)amino]-6-(1H-imidazol-1-yl)-5-phenyl-4-pyrimidinyl]hydrazono]ethyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 850757-43-6 CAPLUS


CN Benzenesulfonamide, 4-[1-[[2-[(5-fluoro-2-methylphenyl)amino]-6-(1H-imidazol-1-yl)-5-phenyl-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI)

(CA INDEX NAME)




RN 850757-58-3 CAPLUS

CN Benzenesulfonamide, 4-[[1-[[2-[(5-fluoro-2-methylphenyl)amino]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-5-phenyl-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 850757-62-9 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-5-phenyl-, [1-(4-pyridinyl)ethylidene]hydrazone (9CI) (CA INDEX NAME)




RN 850758-21-3 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(4-fluorophenyl)amino]-5-phenyl-6-[[2-(4-pyridinyl)ethyl]amino]-, [1-[4-(methylsulfonyl)phenyl]ethylidene]hydrazone (9CI) (CA INDEX NAME)




RN 850758-22-4 CAPLUS

CN Benzenesulfonamide, 4-[1-[[2-[(4-fluorophenyl)amino]-5-phenyl-6-[[2-(4-pyridinyl)ethyl]amino]-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 850758-23-5 CAPLUS

CN Benzenesulfonamide, 4-[1-[[2-[(2-fluorophenyl)amino]-5-phenyl-6-[[2-(4-pyridinyl)ethyl]amino]-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




IT 850707-80-1P 850707-81-2P 850708-07-5P
 850708-08-6P 850708-11-1P 850708-12-2P
 850758-97-3P 850758-98-4P 850759-29-4P
 850759-30-7P 850759-38-5P 850760-01-9P
 850760-10-0P 850760-48-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrimidine compds. as mixed lymphocyte reaction (MLR)
 inhibitors)


RN 850707-80-1 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-6-hydroxy-5-phenyl-
 (9CI) (CA INDEX NAME)




RN 850707-81-2 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-6-hydrazino-5-
 phenyl-, hydrazone (9CI) (CA INDEX NAME)




RN 850708-07-5 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(4-fluorophenyl)amino]-6-hydroxy-5-phenyl- (9CI)
 (CA INDEX NAME)




RN 850708-08-6 CAPLUS

CN 2-Pyrimidinamine, 4,6-dichloro-N-(4-fluorophenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 850708-11-1 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(2-fluorophenyl)amino]-6-hydroxy-5-phenyl- (9CI) (CA INDEX NAME)




RN 850708-12-2 CAPLUS

CN 2-Pyrimidinamine, 4,6-dichloro-N-(2-fluorophenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 850758-97-3 CAPLUS

CN 2-Pyrimidinamine, 4,6-dichloro-N-(5-fluoro-2-methylphenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 850758-98-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-5-phenyl-6-[4-(4-pyridinyl)-1H-pyrazol-1-yl]-, hydrazone (9CI) (CA INDEX NAME)




RN 850759-29-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(2-fluorophenyl)amino]-5-phenyl-, hydrazone (9CI) (CA INDEX NAME)




RN 850759-30-7 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(2-fluorophenyl)amino]-5-phenyl-, hydrazone (9CI) (CA INDEX NAME)




RN 850759-38-5 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-5-phenyl-6-(1H-pyrazol-1-yl)-, hydrazone (9CI) (CA INDEX NAME)




RN 850760-01-9 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-6-(1H-imidazol-1-yl)-5-phenyl-, hydrazone (9CI) (CA INDEX NAME)




RN 850760-10-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-5-phenyl-, hydrazone (9CI) (CA INDEX NAME)



RN 850760-48-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(4-fluorophenyl)amino]-5-phenyl-6-[[2-(4-pyridinyl)ethyl]amino]-, hydrazone (9CI) (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:140796 CAPLUS
 DN 142:240444
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3
 IN Bebbington, David; Charrier, Jean-damien; Golec, Julian; Miller, Andrew; Knegetel, Ronald
 PA UK
 SO U.S. Pat. Appl. Publ., 164 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005038023	A1	20050217	US 2003-632428	20030801
PRAI	US 2003-632428		20030801		
OS	MARPAT 142:240444				

AB The title compds. I [Z1 = N, CR8; Z2 = N, CH; and at least one of Z1 and Z2 = N; Rb, Rc = TR3, LZR3; C2RbRc = (un)substituted fused (hetero)cycle; Q = NR4, O, S, etc.; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2a = R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, etc.; R = H, (un)substituted aliphatic, (hetero)aryl, heterocyclyl; R4 = R7, COR7, SO2R7, etc.; W = CO, CO2, CONR6, etc.; R6, R7 = H, alkyl; or N(R6)2 or N(R7)2 = heterocyclyl, heteroaryl] were prepared For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μ M: GSK-3 β , AURORA-2, CDK-2, ERK2, AKT, and human Src kinase. I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).


IT 438205-79-9P 438205-80-2P 438205-86-8P
 438205-87-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-79-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-80-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-86-8 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-87-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 12 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:120897 CAPLUS
 DN 142:219296
 TI Preparation of 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
 IN Wang, Shudong; McLachlan, Janice; Gibson, Darren; Causton, Ashley; Turner, Nicholas; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012262	A1	20050210	WO 2004-GB3284	20040730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004261484	A1	20050210	AU 2004-261484	20040730
	CA 2533474	AA	20050210	CA 2004-2533474	20040730
	EP 1648875	A1	20060426	EP 2004-743610	20040730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004012347	A	20060905	BR 2004-12347	20040730
	CN 1860104	A	20061108	CN 2004-80028477	20040730
PRAI	GB 2003-17841	A	20030730		
	GB 2003-18345	A	20030805		
	WO 2004-GB3284	W	20040730		

OS MARPAT 142:219296

AB Title compds. I [Z = (un)substituted alkyl, N; R1-2 = (CH2)0-4R11, H, R11, etc.; R3, R5 = H; R4 = H, R11; R6 = H, alkyl; R7, R9 = H, R11; R11 = halo, NO2, CN, etc.] are prepared For instance, [4-(3-Aminophenyl)pyrimidin-2-yl][4-(2-methoxyethoxy)phenyl]amine (II) is prepared from 3-aminoacetophenone, N,N-dimethylformamide di-Me acetal, 2-methoxyethanol and 4-aminophenol. II exhibits IC50 = 0.018 μ M against Cdk9/Cyclin T1. I are tyrosine kinase inhibitors and useful for the treatment of, e.g., rheumatoid arthritis and leukemia.


IT 839727-08-1P, 3-[2-(3-Fluorophenylamino)pyrimidin-4-yl]phenol
 839727-21-8P, [3-[2-[(3-Fluorophenyl)amino]pyrimidin-4-yl]phenyl]methanol 839727-22-9P, (3-Fluorophenyl)[4-(3-methoxyphenyl)pyrimidin-2-yl]amine 839727-23-0P, (3-Fluorophenyl)[4-(4-methoxyphenyl)pyrimidin-2-yl]amine 839727-29-6P, (4-Fluorophenyl)[4-(3-nitrophenyl)pyrimidin-2-yl]amine 839727-30-9P, [4-(3-Aminophenyl)pyrimidin-2-yl](4-fluorophenyl)amine 839727-37-6P, (4-Chlorophenyl)[4-(3-chlorophenyl)pyrimidin-2-yl]amine 839727-66-1P, [4-(2,5-Dimethylphenyl)pyrimidin-2-yl](3-fluorophenyl)amine 839727-67-2P, (3-Fluorophenyl)[4-(3-nitrophenyl)pyrimidin-2-yl]amine 839727-73-0P, 3-[2-[[3,5-Bis(trifluoromethyl)phenyl]amino]pyrimidin-4-yl]phenol

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors)


RN 839727-08-1 CAPLUS

CN Phenol, 3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 839727-21-8 CAPLUS

CN Benzenemethanol, 3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 839727-22-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 839727-23-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 839727-29-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 839727-30-9 CAPLUS

CN 2-Pyrimidinamine, 4-(3-aminophenyl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 839727-37-6 CAPLUS

CN 2-Pyrimidinamine, 4-(3-chlorophenyl)-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 839727-66-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,5-dimethylphenyl)-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 839727-67-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 839727-73-0 CAPLUS

CN Phenol, 3-[2-[[3,5-bis(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:14169 CAPLUS
 DN 142:114470
 TI Preparation of sulfonylated peptide derivatives for treating rheumatoid arthritis
 IN Yednock, Theodore A.; Freedman, Stephen B.; Lieberburg, Ivan; Pleiss, Michael A.; Konradi, Andrei W.; Shopp, George; Messersmith, Elizabeth
 PA Elan Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 736 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000246	A2	20050106	WO 2004-US20280	20040625
	WO 2005000246	A3	20051124		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004251754	A2	20050106	AU 2004-251754	20040625
	AU 2004251754	A1	20050106		
	CA 2529873	AA	20050106	CA 2004-2529873	20040625
	US 2005065192	A1	20050324	US 2004-875282	20040625
	US 2005074451	A1	20050407	US 2004-875469	20040625
	EP 1635822	A2	20060322	EP 2004-777033	20040625
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-482211P	P	20030625		
	WO 2004-US20280	W	20040625		
OS	MARPAT 142:114470				
AB	The invention relates to methods and compns. for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to $\alpha 4$ integrin or an immunol. active antigen binding fragment in therapeutically effective amts. Compds. R1SO2NR2CHR3-Q-CHR5CO2H [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R2 can combine with R1 or R3 to form an (un)substituted heterocyclic group; R5 is -(CH2)1-4-Ar-R5', where R5' is -O-Z-NR8R8' or -O-Z-R8'', Ar is (un)substituted aryl or heteroaryl, Z is CO or SO2, R8, R8' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or NR8R8' is (un)substituted heterocyclyl, and R8'' is (un)substituted heterocyclyl; Q is -C(X)NR7-, where R7 is H or alkyl and X is O or S] are claimed for use in combination therapy. Thus, N-tosyl-L-prolyl-4-(dimethylcarbamoyloxy)-L-phenylalanine Et ester was prepared by acylation of Ts-Pro-Tyr-OEt with dimethylcarbamoyl chloride. Compds. of the invention have binding affinity to $\alpha 4\beta 1$ (IC50 $\leq 15 \mu\text{M}$).				
IT	285139-65-3P 285140-62-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU				


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of sulfonylated peptide derivs. for treating rheumatoid
arthritis)

RN 285139-65-3 CAPLUS

CN L-Tyrosine, N-[2-[(4-chlorophenyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-62-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, α -[[2-[(4-chlorophenyl)methylamino]-5-(2,4,6-trimethylphenyl)-4-pyrimidinyl]amino]-2',6'-dimethoxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:14167 CAPLUS
 DN 142:114469
 TI Preparation of sulfonylated peptide derivatives for treating rheumatoid arthritis
 IN Yednock, Theodore A.; Freedman, Stephen B.; Lieberburg, Ivan; Pleiss, Michael A.; Konradi, Andrei W.; Shopp, George; Messersmith, Elizabeth
 PA Elan Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 647 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000244	A2	20050106	WO 2004-US20240	20040625
	WO 2005000244	A3	20050929		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004251750	A2	20050106	AU 2004-251750	20040625
	AU 2004251750	A1	20050106		
	CA 2528723	AA	20050106	CA 2004-2528723	20040625
	US 2005065192	A1	20050324	US 2004-875282	20040625
	US 2005074451	A1	20050407	US 2004-875469	20040625
	EP 1635871	A2	20060322	EP 2004-777008	20040625
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-482211P	P	20030625		
	WO 2004-US20240	W	20040625		
AB	The invention relates to methods and compns. for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to $\alpha 4$ integrin or an immunol. active antigen binding fragment in therapeutically effective amts. Compds. include those described by formula R1SO2NR2CHR3-Q-CHR5CO2H [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R2 can combine with R1 or R3 to form an (un)substituted heterocyclic group; R5 is -(CH2)1-4-Ar-R5', where R5' is -O-Z-NR8R8' or -O-Z-R8'', Ar is (un)substituted aryl or heteroaryl, Z is CO or SO2, R8, R8' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or NR8R8' is (un)substituted heterocyclyl, and R8'' is (un)substituted heterocyclyl; Q is -C(X)NR7-, where R7 is H or alkyl and X is O or S]. Thus, N-tosyl-L-prolyl-4-(dimethylcarbamoyloxy)-L-phenylalanine Et ester was prepared by acylation of Ts-Pro-Tyr-OEt with dimethylcarbamoyl chloride. Compds. of the invention have binding affinity to $\alpha 4\beta 1$ (IC50 $\leq 15 \mu\text{M}$).				
IT	285139-65-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES				


(Uses)

(preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis)

RN 285139-65-3 CAPLUS

CN L-Tyrosine, N-[2-[(4-chlorophenyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:857162 CAPLUS

DN 141:350185

TI Preparation of pyrimidine derivatives with lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitory activity

IN Bhatt, Rama; Gong, Baoqing; Hong, Feng; Jenkins, Scott A.; Klein, J. Peter; Kohm, Cory T.; Tulinsky, John

PA Cell Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 80 pp., which
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004204386	A1	20041014	US 2003-671070	20030924
PRAI	US 2002-419694P	P	20021017		
	US 2003-460776P	P	20030404		
OS	MARPAT 141:350185				

AB The title compds. I [X, Y, Z = N, CH, or CR with the proviso that two of X, Y and Z are N; R = alkyl, alkoxy, Cl, Br, (substituted)amino; Q = NR', R'-N-(CH₂)_n, (CH₂)_n-NR', O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n, or (CH₂)_n-S; n = 1-10; R' = H or alkyl; R1 = H, OH, alkyl, alkoxy, Cl, F, Br, etc.; R2, R7 = H, OH, alkyl, alkoxy, Cl, F, Br, I, etc.; R3 = H, alkyl, alkoxy, Cl, CC13, (substituted)amino; R4, R5, R6 = H, OH, alkyl, alkenyl, alkynyl, alkoxy, etc. or R4, R5 or R5, R6 are taken together with benzene ring to form a heterocycle] are prepared as lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitors for the treatment of diseases related to cell proliferation, such as cancer. For example, reaction of 6-chloro-N4-(4-methylphenyl)-pyrimidine-2,4-diamine (preparation given) with 5-chloro-2-methoxy-Ph boronic acid yielded compound II. The latter exhibits an IC₅₀ = 0.12 μ M in the LPAAT- β assay.


IT 710334-91-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. with lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitory activity)

RN 710334-91-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N2-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:430750 CAPLUS
 DN 141:7129
 TI Preparation of 4-heteroarylpyrimidines as specific cyclin-dependent kinase inhibitors for treating viruses
 IN Wang, Shudong; Meades, Christopher; Wood, Gavin; Blake, David; Fischer, Peter
 PA Cyclacel Limited, UK
 SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043467	A1	20040527	WO 2003-GB4977	20031114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003283585	A1	20040603	AU 2003-283585	20031114
EP 1581231	A1	20051005	EP 2003-775562	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005288307	A1	20051229	US 2005-129198	20050513
PRAI GB 2002-26582	A	20021114		
WO 2003-GB4977	W	20031114		

OS MARPAT 141:7129

AB Title compds. I [wherein one of X1 and X2 = S, and the other of X1 and X2 = N so as to form a thiazolyl ring, R2 = independently as defined below for R1 and R3; one of X1 and X2 = S, and the other of X1 and X2 = NH and derivs. so as to form a 4,5-dihydrothiazolyl ring; R2 = oxo; the bond between C and R2 = double; Z = NH, NHCO, NHSO2, NHCH2, CH2, CH2CH2, CH:CH; R1, R3 = independently H, halo, NO2, CN, OH and derivs., NH2 and derivs., CO2H and derivs., CONH2 and derivs., SO3H, (un)substituted ar/alkyl, aryl, heterocyclyl, etc.; R4, R5, R6, R7, R8 = independently H, halo, NO2, CN, OH and derivs., NH2 and derivs., alkylheteroaryl, SO3H, SO2NH2, CF3, (un)substituted lower alkyl; and their pharmaceutically acceptable salts] were prepared for use in the treatment of viral disorders. For example, II was prepared by cyclocondensation of 3-Dimethylamino-1-(2,4-dimethylthiazol-5-yl)propenone (preparation given) with N-(3-Nitrophenyl)guanidine nitrate (preparation given) in 2-methoxyethanol in the presence of NaOH. Selected I showed high degree of selectivity for inhibition of CDKs. II displayed an average IC50 of 0.23 μ M against CDK2-Cyclin E1 kinase. Thus, I are useful for treating cytomegalovirus, herpes simplex, HIV-I, and varicella-zoster virus.

IT 364334-28-1P, [4-(2,4-Dimethylthiazol-5-yl)-6-phenylpyrimidin-2-yl] (4-fluorophenyl)amine 364334-31-6P, [4-(2,4-Dimethylthiazol-5-yl)-6-(4-trifluoromethylphenyl)pyrimidin-2-yl] (4-fluorophenyl)amine 364334-32-7P, (4-Chlorophenyl) [4-(2,4-dimethylthiazol-5-yl)-6-(4-trifluoromethylphenyl)pyrimidin-2-yl]amine 364334-35-0P, [4-(2,4-Dimethylthiazol-5-yl)-6-(3-trifluoromethylphenyl)pyrimidin-2-yl] (4-


fluorophenyl)amine 364334-36-1P, 4-[6-(2,4-Dimethylthiazol-5-yl)-
2-(4-fluorophenylamino)pyrimidin-4-yl]-2,6-dimethoxyphenol
364334-37-2P, 4-[6-(2,4-Dimethylthiazol-5-yl)-2-(4-
fluorophenylamino)pyrimidin-4-yl]phenol

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(anti-viral agent; preparation of 4-heteroarylpyrimidines as specific
cyclin-dependent kinase inhibitors for treating viruses)


RN 364334-28-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-phenyl-
(9CI) (CA INDEX NAME)




RN 364334-31-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-32-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-6-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-35-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-36-1 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 364334-37-2 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:412938 CAPLUS
 DN 140:423692
 TI Pyridine and pyrimidine derivatives and their compositions, useful as inhibitors of JAK and other protein kinases
 IN Bethiel, Randy S.; Moon, Young Choon
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041810	A1	20040521	WO 2003-US35188	20031105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507406	AA	20040521	CA 2003-2507406	20031105
AU 2003286895	A1	20040607	AU 2003-286895	20031105
US 2004176271	A1	20040909	US 2003-702113	20031105
EP 1560824	A1	20050810	EP 2003-778111	20031105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508107	T2	20060309	JP 2004-550489	20031105
PRAI US 2002-424043P	P	20021105		
WO 2003-US35188	W	20031105		

OS MARPAT 140:423692

AB The invention provides compds. of formula I or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compns. comprising I, and methods of utilizing I and their compns. in the treatment of various protein kinase-mediated disorders. In compds. I, R1 is Q-Ar1; Q is a bond or C1-2 alkylidene chain wherein one methylene unit is optionally replaced by O, NR, NRCO, NRCONR, NRCO2, CO, CO2, CONR, OC(O)NR, SO2, SO2NR, NRSO2, NRSO2NR, C(O)C(O), or C(O)CH2C(O); R is H or (un)substituted aliphatic; Ar1 is (un)substituted, (poly)(un)saturated, 5- to 7-membered monocyclic ring having 0-3 N/O/S heteroatoms, or 8- to 12-membered bicyclic ring system having 0-5 N/O/S heteroatoms; Z1 is N or CH; Z7 is N or CURy; T, U are bond or (un)saturated C1-6 alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO2, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO2, NRCONR, SO, SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR; Rx, Ry are independently halogen, CN, NO2, or R'; Z2, Z5, and Z6 are independently N or CH, provided that no more than 2 of them are N; Z3 is CR3; Z4 is CR4; wherein one of R3 and R4 is Ru and the other is OR'; Ru is (CH2)tCN, (CH2)tNO2, (CH2)tNR2, (CH2)tNRCOR, (CH2)tCONR2, (CH2)tCO2R, (CH2)tAr2, etc.; t is 0-2; Ar2 is an (un)substituted, (poly)(un)saturated 5- to 7-membered, monocyclic ring having 0-3 N/O/S heteroatoms; and R' is H, (un)substituted aliphatic or (bi)(hetero)cyclic. Approx. 190 compds. I are claimed individually. A general multi-step preparation is described in examples, including step combinations and final product mol. wts. for

approx. 30 invention compds., including II. In a JAK3 inhibition assay, several invention compds. had K_i values less than 0.1 μM . Similar potencies were obtained for some compds. against CDK2, JNK3, SYK, and GSK-3.


IT 691894-96-9P 691894-97-0P 691895-06-4P
691895-07-5P 691895-08-6P 691895-10-0P
691895-24-6P 691895-25-7P 691895-28-0P
691895-29-1P 691895-30-4P 691895-32-6P
691895-36-0P 691895-38-2P 691895-54-2P
691895-55-3P 691895-65-5P 691895-66-6P
691895-67-7P 691895-68-8P 691896-10-3P
691896-11-4P 691896-14-7P 691896-16-9P
691896-19-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridine and pyrimidine derivs. as inhibitors of JAK and other protein kinases)


RN 691894-96-9 CAPLUS

CN 2-Pyrimidinamine, 4-(3-amino-4-methoxyphenyl)-N-(3-fluorophenyl)- (9CI)
(CA INDEX NAME)




RN 691894-97-0 CAPLUS

CN 2-Pyrimidinamine, 4-(3-amino-4-methoxyphenyl)-N-(3-chlorophenyl)- (9CI)
(CA INDEX NAME)




RN 691895-06-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(4-methoxy-3-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 691895-07-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(4-methoxy-3-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 691895-08-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(4-methoxy-3-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 691895-10-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(4-methoxy-3-nitrophenyl)- (9CI)
(CA INDEX NAME)




RN 691895-24-6 CAPLUS

CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)
(CA INDEX NAME)




RN 691895-25-7 CAPLUS

CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)
(CA INDEX NAME)




RN 691895-28-0 CAPLUS

CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)
(CA INDEX NAME)




RN 691895-29-1 CAPLUS

CN Benzamide, 5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-30-4 CAPLUS

CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-32-6 CAPLUS

CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-36-0 CAPLUS

CN Benzamide, 5-[2-[(3,4-difluorophenyl)amino]-4-pyrimidinyl]-2-methoxy-
(9CI) (CA INDEX NAME)




RN 691895-38-2 CAPLUS

CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)
(CA INDEX NAME)




RN 691895-54-2 CAPLUS

CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-
(9CI) (CA INDEX NAME)




RN 691895-55-3 CAPLUS

CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-
(9CI) (CA INDEX NAME)




RN 691895-65-5 CAPLUS

CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-
(9CI) (CA INDEX NAME)




RN 691895-66-6 CAPLUS

CN Benzamide, 5-[2-[(3,4-difluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-67-7 CAPLUS

CN Benzamide, 5-[2-[(4-chloro-3-cyanophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-68-8 CAPLUS

CN Benzamide, 5-[2-[(3,5-dichlorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691896-10-3 CAPLUS

CN Phenol, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 691896-11-4 CAPLUS

CN Phenol, 4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 691896-14-7 CAPLUS

CN Phenol, 4-[2-[(3-chloro-4-methoxyphenyl)amino]-4-pyrimidinyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 691896-16-9 CAPLUS

CN Phenol, 4-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 691896-19-2 CAPLUS


CN Phenol, 2-amino-4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:303311 CAPLUS
 DN 141:64387
 TI Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: inhibitors of lysophosphatidic acid acyltransferase- β
 AU Gong, Baoqing; Hong, Feng; Kohm, Cory; Jenkins, Scott; Tulinsky, John; Bhatt, Rama; de Vries, Peter; Singer, Jack W.; Klein, Peter
 CS Cell Therapeutics, Inc., Seattle, WA, 98119, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(9), 2303-2308
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 141:64387
 AB 2,4-Diamino-N4,6-diarylpyrimidines were identified as potent, isoform specific inhibitors of lysophosphatidic acid acyltransferase- β (LPAAT- β). Active inhibitors also blocked proliferation of tumor cell lines in vitro. The effect of one of the synthesized compds. (2j) in an in vivo tumor model was investigated.
 IT 710334-91-1P 710334-92-2P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers, inhibitors of lysophosphatidic acid acyltransferase- β)
 RN 710334-91-1 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N2-(4-chlorophenyl)-(9CI) (CA INDEX NAME)



RN 710334-92-2 CAPLUS
 CN 2,4-Pyrimidinediamine, N2-(4-bromophenyl)-6-(5-chloro-2-methoxyphenyl)-(9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:182368 CAPLUS
 DN 140:229401
 TI Three hybrid assay system for isolating ligand-binding polypeptides and
 for isolating small mol. ligands
 IN Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
 PA Gpc Biotech Inc., USA; Gpc Biotech AG
 SO U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004043388	A1	20040304	US 2002-234985	20020903
	US 7135550	B2	20061114		
	US 2003165873	A1	20030904	US 2002-91177	20020304
	US 2004266854	A1	20041230	US 2004-820453	20040407
PRAI	US 2001-272932P	P	20010302		
	US 2001-278233P	P	20010323		
	US 2001-329437P	P	20011015		
	US 2002-91177	A2	20020304		
	US 2001-336962P	P	20011203		
	WO 2002-US6677	A2	20020304		
	US 2002-234985	A2	20020903		
	WO 2002-US33052	A2	20021015		
	US 2003-460921P	P	20030407		
	US 2003-531872P	P	20031223		

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.

IT 273920-44-8D, conjugates.
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 273920-44-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)amino]-1,4-dihydro-4-oxo-6-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:162676 CAPLUS
 DN 140:199343
 TI Preparation of aminopyrimidine derivatives as protein kinase inhibitors
 IN Cochran, John; Green, Jeremy; Hale, Michael R.; Ledford, Brian; Maltais, Francois; Nanthakumar, Suganthini
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 179 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016597	A2	20040226	WO 2003-US25333	20030812
	WO 2004016597	A3	20040422		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2495386	AA	20040226	CA 2003-2495386	20030812
	AU 2003262642	A1	20040303	AU 2003-262642	20030812
	US 2004106615	A1	20040603	US 2003-639784	20030812
	BR 2003013397	A	20050628	BR 2003-13397	20030812
	EP 1546117	A2	20050629	EP 2003-788433	20030812
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006506462	T2	20060223	JP 2005-502048	20030812
	NO 2005001207	A	20050518	NO 2005-1207	20050308
PRAI	US 2002-403256P	P	20020814		
	US 2002-416802P	P	20021008		
	WO 2003-US25333	W	20030812		
OS	MARPAT 140:199343				

AB Title compds. I [wherein B = 6-membered aryl ring with 0-3 N atoms, Z1, Z2 = independently N, CH; T, Q = independently saturated or unsatd. alkylidene; U = NH and derivs., NHCO2 and derivs., o, CONH and derivs., CO, CO2, OCO, NHSO2 and derivs., SO2NH and derivs., SO2, etc.; m, n = independently 0 or 1; p = 0-4; R1 = R or Ar; R = H, (un)substituted aliphatic group; Ar = (un)substituted 6-10 membered aryl ring, 5-10 membered heteroaryl ring having 1-4 heteroatoms, or a 3-10 heterocyclyl membered ring having 1-4 heteroatoms; R3 = R, Ar, (CH2)yCH(R5)2 or CN; y = 0-6; R2 = (CH2)yCH(R5)2, (CH2)yCH(R4)CH(R5)2; R4 = R, (CH2)wOR, (CH2)wN(R)2 or (CH2)wSR; w = 0-4; R5 = independently Ar, OR, CO2R, SR, SO2R, CN, N(Ar)(R), (un)substituted aliphatic, etc.; R6 = independently R, F, Cl, NH2 and derivs., OR, SR, SO2R, NRSO2R, CN, SO2N(R)2, etc.; and their pharmaceutically acceptable salts] were prepared as protein kinase inhibitors (no data). For example, II was prepared in 3 steps by Pd-cross coupling of 2,4-dichloro-5-fluoropyrimidine with 4-methoxycarbonylphenyl boronic acid (III), acylation of (S)-3-chlorophenyl glycinol with III, and alkylation of isopropylamine with 2-chloropyrimidine intermediate. I and their formulations are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE

lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation (no data).


IT 663612-09-7P 663612-13-3P 663612-15-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)


RN 663612-09-7 CAPLUS

CN 4-Morpholineacetamide, N-[4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]phenyl]- α -phenyl- (9CI) (CA INDEX NAME)




RN 663612-13-3 CAPLUS

CN 4-Morpholineacetamide, α -phenyl-N-[4-[2-[(3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 663612-15-5 CAPLUS


CN 4-Morpholineacetamide, N-[4-[2-[(3-bromophenyl)amino]-4-pyrimidinyl]phenyl]- α -phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 21 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:1001978 CAPLUS
 DN 140:314405
 TI A novel series of potent and selective IKK2 inhibitors
 AU Bingham, Alistair H.; Davenport, Richard J.; Gowers, Lewis; Knight, Roland L.; Lowe, Christopher; Owen, David A.; Parry, David M.; Pitt, Will R.
 CS Celltech R&D Ltd, Great Abington, Cambridge, CB16GS, UK
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(2), 409-412
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 140:314405
 AB A novel series of aminopyrimidine IKK2 inhibitors have been developed which show excellent in vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative potency and selectivity of these compds. has been rationalized using QSAR and structure-based modeling.
 IT 677753-07-0P 677753-13-8P 677753-14-9P
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and QSAR studies of series of potent and selective aminopyrimidine IKK2 inhibitors)
 RN 677753-07-0 CAPLUS
 CN Piperazine, 1-[[4-[2-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 677753-13-8 CAPLUS
 CN Piperazine, 1-[[4-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 677753-14-9 CAPLUS
 CN Piperazine, 1-[[4-[2-[(3,5-difluorophenyl)amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




IT 677752-85-1P 677752-91-9P 677752-93-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and QSAR studies of series of potent and selective aminopyrimidine IKK2 inhibitors)


RN 677752-85-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[2-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677752-91-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[2-[[4-(4-chlorophenyl)amino]-4-pyrimidinyl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677752-93-1 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[4-[2-[[4-(3,5-difluorophenyl)amino]-4-pyrimidinyl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:907999 CAPLUS
 DN 141:89052.
 TI Polymer-assisted synthesis of ethyl 2-amino-4,6-diarylpyrimidine-5-carboxylates
 AU Vanden Eynde, Jean Jacques; Labuche, Nadege; Van Haverbeke, Yves; Tietze, Lutz
 CS College of Pharmacy, Division of Basic Pharmaceutical Sciences, Xavier University of Louisiana, New Orleans, LA, 70125, USA
 SO ARKIVOC (Gainesville, FL, United States) (2003), (15), 22-28
 CODEN: AGFUAR
 URL: [http://www.arkat-usa.org/ark/journal/2003/General_Part\(xv\)/03-805B/805B.pdf](http://www.arkat-usa.org/ark/journal/2003/General_Part(xv)/03-805B/805B.pdf)
 PB Arkat USA Inc.
 DT Journal; (online computer file)
 LA English
 OS CASREACT 141:89052
 AB Et 2-amino-4,6-diarylpyrimidine-5-carboxylatesI [R1 = H; R2 = Ph, 4-ClC6H4, 4-MeOC6H4, n-Bu; R3 = H; R2R3 = (CH2)4, (CH2)2O(CH2)2; R1 = H, MeO, O2N; R2 = R3 = Me] have been synthesized in modest to good yields by a five-step procedure that involves building of the heterocyclic moiety on a solid support derived from Merrifield resin and final displacement with an amine.
 IT 714250-71-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of amino(diaryl)pyrimidinecarboxylates via substitution of Merrifield resin with thiourea followed by heterocyclization with arylidene(benzoyl)acetates followed by double oxidation and resin cleavage with amines)
 RN 714250-71-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 2-[(4-chlorophenyl)amino]-4,6-diphenyl-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:610266 CAPLUS
 DN 139:164802
 TI Phenylpyrimidine amines and amides as IgE inhibitors and their
 pharmaceutical compositions and therapeutic uses
 IN Bulusu, Murty; Ettmayer, Peter; Weigand, Klaus; Woisetschlaeger, Max
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Appl


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063871	A1	20030807	WO 2003-EP973	20030131
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA 2471883	AA	20030807	CA 2003-2471883	20030131
	EP 1474146	A1	20041110	EP 2003-704506	20030131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007379	A	20041228	BR 2003-7379	20030131
	NZ 534229	A	20050429	NZ 2003-534229	20030131
	CN 1622807	A	20050601	CN 2003-802737	20030131
	JP 2005516051	T2	20050602	JP 2003-563561	20030131
	US 2005119255	A1	20050602	US 2003- 501445	20030131
	NO 2004003610	A	20041005	NO 2004-3610	20040830
PRAI	GB 2002-2381	A	20020201		
	GB 2002-21953	A	20020920		
	WO 2003-EP973	W	20030131		

OS MARPAT 139:164802


AB Title amines I are disclosed [wherein: R1 = halo, halo(C1-4)alkyl; R2 = H, halo, halo(C1-4)alkyl; R3 = halo, halo(C1-4)alkyl; R4 = H, C1-8 alkyl, hydroxy(C1-6)alkyl, various acyl groups, including formyl, (un)substituted alkanoyl, aroyl, carbamoyl, and oxycarbonyls]. I are useful as IgE biosynthesis inhibitors. Claimed uses include therapy of IgE-synthesis-mediated diseases, autoimmune diseases, gastrointestinal diseases, and chronic rejection of transplants. Targeted diseases include allergic asthma and other allergic and inflammatory diseases. Over 70 invention compds. and/or salts were prepared For instance, 3-chloroacetophenone was condensed with DMF di-Me acetal to give 3-ClC6H4COCH:CHNMe2 (II). Addition reaction of 4-trifluoromethylaniline with cyanamide in aqueous solution in the presence of HCl gave N-[4-(trifluoromethyl)phenyl]guanidine, isolated as the carbonate (III). Cyclocondensation of II with III in n-BuOH at 120° gave invention compound IV [R4 = H]. Treatment of this with phosgene and then MeN(CH2CH2OH)2 gave the derivative IV [R4 = COOCH2CH2N(Me)CH2CH2OH], isolated as the HCl salt. Compds. I (R4 ≠ H) were less stable in human and murine plasma than compds. I (R4 = H) (no data), and may thus be considered to be prodrugs of the latter. The outcomes of several bioassays are also described (no data). I inhibit IgE production preferentially over IgG. I also inhibit IL-4 and anti-CD40 antibody

mediated B-cell proliferation above the concns. needed to block IgE synthesis. I modulated DC cell surface markers, inhibiting the expression levels of CD86, HLA-Dr, CD83, and CD25. I also inhibited DC-mediated T-cell proliferation and cytokine production


IT 574759-62-9P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]amine 574760-05-7P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-4-(methoxycarbonyl)butanamide 574760-06-8P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-5-(methoxycarbonyl)pentanamide 574760-10-4P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-4-carboxybutanamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; phenylpyrimidine amines as IgE inhibitors and their pharmaceutical compns. and therapeutic uses)
 RN 574759-62-9 CAPLUS
 CN 2-Pyrimidinamine, 4-(3-chlorophenyl)-N-[4-(trifluoromethyl)phenyl]- (9CI)
 (CA INDEX NAME)



RN 574760-05-7 CAPLUS
 CN Pentanoic acid, 5-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 574760-06-8 CAPLUS
 CN Hexanoic acid, 6-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 574760-10-4 CAPLUS

CN Pentanoic acid, 5-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



IT 574759-63-0P, N-[4-[3-(Trifluoromethyl)phenyl]pyrimidin-2-yl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]amine 574759-64-1P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-chloro-3-(trifluoromethyl)phenyl]amine 574759-65-2P, N-[4-[3-(Trifluoromethyl)phenyl]pyrimidin-2-yl]-N-[4-chloro-3-(trifluoromethyl)phenyl]amine 574759-66-3P, N-[4-[3-(Trifluoromethyl)phenyl]pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]amine 574759-67-4P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]acetamide 574759-68-5P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]propanamide 574759-69-6P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2-methylpropanamide 574759-70-9P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]benzamide 574759-71-0P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-3-methylbutanamide 574759-72-1P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-α-oxobenzeneacetamide 574759-73-2P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2,2-dimethylpropanamide 574759-74-3P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]cyclohexanecarboxamide 574759-75-4P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide 574759-76-5P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2-ethoxy-2-oxoacetamide 574759-77-6P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2-acetoxyacetamide 574759-78-7P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2-methoxy-2-oxoacetamide 574759-79-8P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]cyclopropanecarboxamide 574759-80-1P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2-

methoxyacetamide 574759-81-2P, (S)-N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2-acetoxypentanamide 574759-82-3P 574759-83-4P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 3-aminopropyl ester hydrochloride 574759-84-5P, (S)-[4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-aminopropyl ester hydrochloride 574759-85-6P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-[(2-hydroxyethyl)amino]ethyl ester hydrochloride 574759-86-7P, (S)-[4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid (pyrrolidin-2-yl)methyl ester hydrochloride 574759-87-8P, (S)-[4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-aminoethyl ester hydrochloride 574759-88-9P, (S)-[4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-amino-2-carboxyethyl ester hydrochloride 574759-89-0P 574759-90-3P 574759-91-4P 574759-93-6P 574759-94-7P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-[(2-hydroxyethyl)(methyl)amino]ethyl ester hydrochloride 574759-95-8P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid ethyl ester 574759-96-9P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-(morpholin-4-yl)ethyl ester hydrochloride 574759-97-0P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-(pyrrolidin-1-yl)ethyl ester hydrochloride 574759-98-1P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 3-(dimethylamino)propyl ester hydrochloride 574759-99-2P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 3-hydroxypropyl ester 574760-00-2P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-(dimethylamino)ethyl ester hydrochloride 574760-01-3P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethyl ester hydrochloride 574760-02-4P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-(4-methylpiperazin-1-yl)ethyl ester 574760-03-5P, [4-(3-Chlorophenyl)pyrimidin-2-yl](methyl)[4-(trifluoromethyl)phenyl]amine 574760-04-6P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-N',N'-dimethylurea 574760-07-9P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-3-(methoxycarbonyl)propanamide 574760-08-0P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2-[(methoxycarbonyl)methoxy]acetamide 574760-09-1P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-2-(2-methoxyethoxy)acetamide 574760-11-5P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-5-carboxypentanamide 574760-12-6P 574760-13-7P 574760-14-8P 574760-15-9P 574760-16-0P 574760-17-1P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-3-(diethylcarbamoyl)propanamide 574760-18-2P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-3-[N-[3-(dimethylamino)propyl]carbamoyl]propanamide 574760-19-3P 574760-20-6P 574760-21-7P 574760-22-8P 574760-23-9P 574760-24-0P 574760-25-1P 574760-26-2P 574760-27-3P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-4-(N,N-diethylcarbamoyl)butanamide 574760-28-4P, N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-4-[N-[3-(dimethylamino)propyl]carbamoyl]butanamide 574760-29-5P,


N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-3-[[5-(2-carboxyethoxy)pentyl]oxy]propanamide 574760-30-8P,
 [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid
 3-[(S)-2-aminopropionyl]amino]propyl ester hydrochloride
 574760-32-0P 574760-33-1P, [4-(3-Chlorophenyl)pyrimidin-
 2-yl][4-(trifluoromethyl)phenyl]carbamic acid 2-[(2-
 hydroxyethyl)(methyl)amino]ethyl ester 574760-34-2P,
 [4-(3-Chlorophenyl)pyrimidin-2-yl](4-trifluoromethylphenyl)carbamic acid
 2-[(2-hydroxyethyl)(methyl)amino]ethyl ester mesylate 574760-35-3P
 , [4-(3-Chlorophenyl)pyrimidin-2-yl](4-trifluoromethylphenyl)carbamic acid
 2-[(2-hydroxyethyl)(methyl)amino]ethyl ester sulfate 574760-36-4P
 , [4-(3-Chlorophenyl)pyrimidin-2-yl](4-trifluoromethylphenyl)carbamic acid
 2-[(2-hydroxyethyl)(methyl)amino]ethyl ester tartrate 574760-37-5P
 , [4-(3-Chlorophenyl)pyrimidin-2-yl](4-trifluoromethylphenyl)carbamic acid
 2-[(2-hydroxyethyl)(methyl)amino]ethyl ester tosylate 574760-38-6P
 , [4-(3-Chlorophenyl)pyrimidin-2-yl](4-trifluoromethylphenyl)carbamic acid
 2-[(2-hydroxyethyl)(methyl)amino]ethyl ester besylate 574760-39-7P
 , N-[4-(3-Chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]-4-
 carboxybutanamide calcium salt

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; phenylpyrimidine amines as IgE inhibitors and their
 pharmaceutical compns. and therapeutic uses)


RN 574759-63-0 CAPLUS

CN 2-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-4-[3-
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-64-1 CAPLUS

CN 2-Pyrimidinamine, 4-(3-chlorophenyl)-N-[4-chloro-3-
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-65-2 CAPLUS

CN 2-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[3-
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-66-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-67-4 CAPLUS

CN Acetamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 574759-68-5 CAPLUS

CN Propanamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-69-6 CAPLUS

CN Propanamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-2-methyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 574759-70-9 CAPLUS

CN Benzamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-71-0 CAPLUS

CN Butanamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-3-methyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 574759-72-1 CAPLUS

CN Benzeneacetamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-α-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-73-2 CAPLUS

CN Propanamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-2,2-dimethyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-74-3 CAPLUS

CN Cyclohexanecarboxamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-75-4 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]tetrahydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-76-5 CAPLUS

CN Acetic acid, [[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 574759-77-6 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574759-78-7 CAPLUS

CN Acetic acid, [[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 574759-79-8 CAPLUS

CN Cyclopropanecarboxamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 574759-80-1 CAPLUS


CN Acetamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-2-methoxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 574759-81-2 CAPLUS

CN Propanamide, 2-(acetyloxy)-N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N-[4-(trifluoromethyl)phenyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574759-82-3 CAPLUS


CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 3-[[[(2S)-2-amino-1-oxopropyl]amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 574759-83-4 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 3-aminopropyl ester, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 574759-84-5 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, (2S)-2-aminopropyl ester, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 574759-85-6 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[(2-hydroxyethyl)amino]ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 574759-86-7 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, (2S)-2-pyrrolidinymethyl ester, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 574759-87-8 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-aminoethyl ester, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 574759-88-9 CAPLUS

CN L-Serine, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]carbamate (ester), hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 574759-89-0 CAPLUS

CN D-Alanine, 2-[[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]carbonyl]oxy]ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 574759-90-3 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[[2R)-2-amino-1-oxopropyl]amino]ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 574759-91-4 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[[2R,3R)-2-amino-3-hydroxy-1-oxobutyl]amino]ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 574759-93-6 CAPLUS
 CN L-Alanine, 3-[[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]carbonyl]oxy]propyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 574759-92-5
 CMF C24 H22 Cl F3 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 574759-94-7 CAPLUS
 CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[(2-hydroxyethyl)methylamino]ethyl ester,


hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 574759-95-8 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 574759-96-9 CAPLUS


CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-(4-morpholinyl)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 574759-97-0 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-(1-pyrrolidinyl)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




RN 574759-98-1 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 3-(dimethylamino)propyl ester, hydrochloride (9CI) (CA INDEX NAME)




RN 574759-99-2 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 3-hydroxypropyl ester (9CI) (CA INDEX NAME)



RN 574760-00-2 CAPLUS


CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-(dimethylamino)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 574760-01-3 CAPLUS


CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 574760-02-4 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-(4-methyl-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 574760-03-5 CAPLUS

CN 2-Pyrimidinamine, 4-(3-chlorophenyl)-N-methyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574760-04-6 CAPLUS

CN Urea, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N',N'-dimethyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 574760-07-9 CAPLUS


CN Butanoic acid, 4-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 574760-08-0 CAPLUS


CN Acetic acid, [2-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

INDEX NAME)




RN 574760-09-1 CAPLUS

CN Acetamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-2-(2-methoxyethoxy)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 574760-11-5 CAPLUS


CN Hexanoic acid, 6-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-6-oxo- (9CI) (CA INDEX NAME)



RN 574760-12-6 CAPLUS

CN L-Alanine, N-[4-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574760-13-7 CAPLUS

CN L-Alanine, N-[5-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,5-dioxopentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574760-14-8 CAPLUS

CN L-Alanine, N-[[2-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574760-15-9 CAPLUS

CN L-Alanine, N-[4-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,4-dioxobutyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574760-16-0 CAPLUS


CN L-Phenylalanine, N-[5-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,5-dioxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 574760-17-1 CAPLUS

CN Butanediamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N',N'-diethyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 574760-18-2 CAPLUS


CN Butanediamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N'-[3-(dimethylamino)propyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 574760-19-3 CAPLUS

CN L-Glutamic acid, N-[4-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,4-dioxobutyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574760-20-6 CAPLUS

CN L-Phenylalanine, N-[4-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574760-21-7 CAPLUS

CN L-Glutamic acid, N-[4-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,4-dioxobutyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574760-22-8 CAPLUS

CN L-Glutamic acid, N-[5-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,5-dioxopentyl]-, dimethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 574760-23-9 CAPLUS

CN L-Glutamic acid, N-[5-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,5-dioxopentyl]-, 5-methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 574760-24-0 CAPLUS

CN L-Alanine, N-[5-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,5-dioxopentyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 574760-25-1 CAPLUS

CN L-Alanine, N-[[2-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-2-oxoethoxy]acetyl]-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 574760-26-2 CAPLUS


CN L-Lysine, N2-acetyl-N6-[4-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 574760-27-3 CAPLUS

CN Pentanediamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N',N'-diethyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 574760-28-4 CAPLUS

CN Pentanediamide, N-[4-(3-chlorophenyl)-2-pyrimidinyl]-N'-[3-(dimethylamino)propyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 574760-29-5 CAPLUS


CN Propanoic acid, 3-[[5-[3-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-3-oxopropoxy]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 574760-30-8 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 3-[[[(2S)-2-amino-1-oxopropyl]amino]propyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 574760-32-0 CAPLUS


CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[[2-(2-amino-1-oxopropyl)amino]ethyl] ester, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 574760-31-9

CMF C23 H21 Cl F3 N5 O3


Absolute stereochemistry.



CM 2

CRN 98-11-3


CMF C6 H6 O3 S



RN 574760-33-1 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-

(trifluoromethyl)phenyl]-, 2-[(2-hydroxyethyl)methylamino]ethyl ester
(9CI) (CA INDEX NAME)




RN 574760-34-2 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[(2-hydroxyethyl)methylamino]ethyl ester, methanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 574760-33-1


CMF C23 H22 Cl F3 N4 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 574760-35-3 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[(2-hydroxyethyl)methylamino]ethyl ester, sulfate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 574760-33-1
CMF C23 H22 Cl F3 N4 O3



CM 2


CRN 7664-93-9
CMF H2 O4 S



RN 574760-36-4 CAPLUS
CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[(2-hydroxyethyl)methylamino]ethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 574760-33-1
CMF C23 H22 Cl F3 N4 O3



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 574760-37-5 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[(2-hydroxyethyl)methylamino]ethyl ester, 4-methylbenzenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 574760-33-1


CMF C23 H22 Cl F3 N4 O3



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 574760-38-6 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 2-[(2-hydroxyethyl)methylamino]ethyl ester, benzenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 574760-33-1


CMF C23 H22 Cl F3 N4 O3



CM 2


CRN 98-11-3

CMF C6 H6 O3 S



RN 574760-39-7 CAPLUS

CN Pentanoic acid, 5-[[4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]amino]-5-oxo-, calcium salt (9CI) (CA INDEX NAME)



● 1/2 Ca


IT 574760-41-1P, [4-(3-Chlorophenyl)pyrimidin-2-yl][4-(trifluoromethyl)phenyl]carbamic acid 3-[[(S)-2-[(tert-butoxycarbonyl)amino]propionyl]amino]propyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; phenylpyrimidine amines as IgE inhibitors and their pharmaceutical compns. and therapeutic uses)

RN 574760-41-1 CAPLUS

CN Carbamic acid, [4-(3-chlorophenyl)-2-pyrimidinyl][4-(trifluoromethyl)phenyl]-, 3-[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:777933 CAPLUS

DN 137:294969

TI 4-Aryl-substituted 2-pyrimidinamines and 2-pyridinamines, useful as inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

IN Bethiel, Randy; Cochran, John; Moon, Young-Choon; Nanthakumar, Susanthini

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079197	A1	20021010	WO 2002-US9554	20020328
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2441733	AA	20021010	CA 2002-2441733	20020328
	US 2003087922	A1	20030508	US 2002-109070	20020328
	US 6949544	B2	20050927		
	EP 1373257	A1	20040102	EP 2002-725391	20020328
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004529140	T2	20040924	JP 2002-577822	20020328
PRAI	US 2001-279961P	P	20010329		
	WO 2002-US9554	W	20020328		

OS MARPAT 137:294969


AB The invention provides compds. of formula I and II, and their pharmaceutically acceptable derivs. [wherein: W = N, CH; R₁, R₂, R₃ = halo, QR, QnCN, QnNO₂, QnAr₂; or R₁R₂, R₂R₃ = 4- to 8-membered (un)saturated ring with 0-3 N/O/S atoms; n = 0 or 1; Q = C1-4 alkylidene with one CH₂ optionally replaced by O, S, NR, NRCO, CO, CO₂, CONR, SO₂, SO₂NR, NRSO₂NR, etc.; R = H, (un)substituted aliphatic; or NRR = 3- to 7-membered (un)saturated ring with 1-2 addnl. N/O/S atoms; R₄ = Ar₁, TAr₂, TnAr₃; T = C1-2 alkylidene with optional replacement of a CH₂ as above; Ar₁ = (un)substituted 5- to 6-membered mono- or bicyclic (un)saturated ring system; Ar₂ = (un)substituted 5- to 6-membered (un)saturated monocyclic ring with 0-3 N/O/S atoms, or (un)substituted 8- to 10-membered (un)saturated bicyclic ring with 0-5 N/O/S atoms; Ar₃ = 6-membered aryl with 0-2 N atoms and substituted with certain groups; with provisos and exclusions]. The compds. are inhibitors of protein kinases, particularly JNK, a mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. Furthermore, they are inhibitors of Src-family kinases, especially Src and Lck kinases. The compds. are also inhibitors of GSK3 and CDK2 kinases. The invention also relates to methods for producing the compds. Also provided are pharmaceutical compns. comprising I or II, and methods of utilizing those compns. in the treatment and prevention of various disorders. Three tables of approx. 240 compds. were prepared and claimed., and most were tested against at least one of the five mentioned kinases. For instance, 3,4-dihydroxy-5-methoxybenzaldehyde was

cyclized with 1,2-dibromoethane to give a benzodioxane derivative, followed by elaboration of the formyl group to Me₂NCH:CH:CO- in 3 steps. Cyclization of the resultant enaminone with 3-chlorophenylguanidine gave title compound III. This compound inhibited cloned human JNK3 protein in vitro with K_i < 0.1 μM.


IT 468084-18-6P, 4-(3,4,5-Trimethoxyphenyl)-N-(4-chlorophenyl)-2-pyrimidinamine 468084-19-7P, 4-(3,4,5-Trimethoxyphenyl)-N-(2,6-difluorophenyl)-2-pyrimidinamine 468084-20-0P
 468084-22-2P, 4-(3,4,5-Trimethoxyphenyl)-N-(2-fluorophenyl)-2-pyrimidinamine 468084-23-3P 468084-29-9P,
 4-(3,4,5-Trimethoxyphenyl)-N-(2,3-difluorophenyl)-2-pyrimidinamine 468084-32-4P, 4-(3,4,5-Trimethoxyphenyl)-N-(3-chlorophenyl)-2-pyrimidinamine 468084-33-5P, 4-(3,4,5-Trimethoxyphenyl)-N-(3-(trifluoromethyl)phenyl)-2-pyrimidinamine 468084-36-8P,
 4-(3,4,5-Trimethoxyphenyl)-N-(3,4,5-trifluorophenyl)-2-pyrimidinamine 468084-37-9P, 4-(3,4,5-Trimethoxyphenyl)-N-(3,5-dichlorophenyl)-2-pyrimidinamine 468084-53-9P, 4-(3,4,5-Trimethoxyphenyl)-N-(3-chloro-4-methoxyphenyl)-2-pyrimidinamine 468084-58-4P,
 4-(3,5-Dimethoxy-4-(2-morpholinoethoxy)phenyl)-N-(3-chlorophenyl)-2-pyrimidinamine 468084-59-5P, 4-(4-Ethoxy-3,5-dimethoxyphenyl)-N-(3-chlorophenyl)-2-pyrimidinamine 468084-60-8P,
 4-(3,5-Dichloro-4-methoxyphenyl)-N-(3-chlorophenyl)-2-pyrimidinamine 468084-61-9P, 4-(3,5-Dimethyl-4-methoxyphenyl)-N-(3-chlorophenyl)-2-pyrimidinamine 468084-62-0P, 4-(3,5-Dibromo-4-methoxyphenyl)-N-(3-chlorophenyl)-2-pyrimidinamine 468084-63-1P,
 4-(3,5-Dimethoxy-4-(2-morpholinoethoxy)phenyl)-N-(3-fluorophenyl)-2-pyrimidinamine 468084-64-2P, 4-(4-Ethoxy-3,5-dimethoxyphenyl)-N-(3-fluorophenyl)-2-pyrimidinamine 468084-65-3P,
 4-(3,5-Dichloro-4-methoxyphenyl)-N-(3-fluorophenyl)-2-pyrimidinamine 468084-66-4P, 4-(3,5-Dimethyl-4-methoxyphenyl)-N-(3-fluorophenyl)-2-pyrimidinamine 468084-67-5P, 4-(3,5-Dibromo-4-methoxyphenyl)-N-(3-fluorophenyl)-2-pyrimidinamine 468084-77-7P,
 4-(3,4,5-Trimethoxyphenyl)-N-(3-bromophenyl)-2-pyrimidinamine 468085-90-7P, 4-(2,3,4-Trimethoxyphenyl)-N-(3-fluorophenyl)-2-pyrimidinamine 468085-92-9P, 4-(2,3,4-Trimethoxyphenyl)-N-(4-fluorophenyl)-2-pyrimidinamine 468085-93-0P,
 4-(2,3,4-Trimethoxyphenyl)-N-(4-chlorophenyl)-2-pyrimidinamine 468085-94-1P, 4-(2,3,4-Trimethoxyphenyl)-N-(3,4-difluorophenyl)-2-pyrimidinamine 468086-56-8P, 4-(2,3,4-Trimethoxyphenyl)-N-(3'-chloro-4-fluoro-1,1'-biphenyl-3-yl)-2-pyrimidinamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phenyl-substituted pyridinamines and pyrimidinamines as inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases)
 RN 468084-18-6 CAPLUS
 CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI)
 (CA INDEX NAME)



RN 468084-19-7 CAPLUS


CN 2-Pyrimidinamine, N-(2,6-difluorophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)

RN 468084-20-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)


RN 468084-22-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 468084-23-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 468084-29-9 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-difluorophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 468084-32-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 468084-33-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(trifluoromethyl)phenyl]-4-(3,4,5-trimethoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 468084-36-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,4,5-trifluorophenyl)-4-(3,4,5-trimethoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 468084-37-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dichlorophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 468084-53-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 468084-58-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[3,5-dimethoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 468084-59-5 CAPLUS


CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(4-ethoxy-3,5-dimethoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 468084-60-8 CAPLUS
 CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(3,5-dichloro-4-methoxyphenyl)-
 (9CI) (CA INDEX NAME)



RN 468084-61-9 CAPLUS
 CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(4-methoxy-3,5-dimethylphenyl)-
 (9CI) (CA INDEX NAME)




RN 468084-62-0 CAPLUS
 CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(3,5-dibromo-4-methoxyphenyl)-
 (9CI) (CA INDEX NAME)




RN 468084-63-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3,5-dimethoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468084-64-2 CAPLUS

CN 2-Pyrimidinamine, 4-(4-ethoxy-3,5-dimethoxyphenyl)-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468084-65-3 CAPLUS

CN 2-Pyrimidinamine, 4-(3,5-dichloro-4-methoxyphenyl)-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468084-66-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(4-methoxy-3,5-dimethylphenyl)-
(9CI) (CA INDEX NAME)




RN 468084-67-5 CAPLUS

CN 2-Pyrimidinamine, 4-(3,5-dibromo-4-methoxyphenyl)-N-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 468084-77-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA
INDEX NAME)




RN 468085-90-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(2,3,4-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 468085-92-9 CAPLUS


CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(2,3,4-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)



RN 468085-93-0 CAPLUS


CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,3,4-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)

RN 468085-94-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-difluorophenyl)-4-(2,3,4-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)

RN 468086-56-8 CAPLUS

CN 2-Pyrimidinamine, N-(3'-chloro-4-fluoro[1,1'-biphenyl]-3-yl)-4-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:615605 CAPLUS
 DN 137:169539
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease
 IN Bebbington, David; Charrier, Jean-Damien; Golec, Julian M. C.; Miller, Andrew; Knegetel, Ronald
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 335 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 14

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002062789	A1	20020815	WO 2001-US51031	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2432222	AA	20020815	CA 2001-2432222	20011219
CA 2432303	AA	20020829	CA 2001-2432303	20011219
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432223	AA	20020906	CA 2001-2432223	20011219
WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003004161	A1	20030102	US 2001-26975	20011219
US 6653300	B2	20031125		
US 2003036543	A1	20030220	US 2001-25164	20011219
US 6664247	B2	20031216		
US 2003055068	A1	20030320	US 2001-26967	20011219
US 6989385	B2	20060124		

US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345927	A1	20030924	EP 2001-994510	20011219
EP 1345927	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518703	T2	20040624	JP 2002-563142	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
HU 200400638	A2	20040628	HU 2004-638	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
HU 200400842	A2	20040728	HU 2004-842	20011219
US 2004214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
NZ 526471	A	20050826	NZ 2001-526471	20011219
AT 327989	E	20060615	AT 2001-271061	20011219
AT 326460	E	20060615	AT 2001-985059	20011219
AT 326461	E	20060615	AT 2001-993360	20011219
AT 326462	E	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 340172	E	20061015	AT 2001-994323	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	E	20060615	AT 2001-994347	20011220
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613
NO 2003002736	A	20030818	NO 2003-2736	20030616
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321

AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
PRAI US 2000-257887P	P	20001221		
US 2001-286949P	P	20010427		
US 2000-232795P	P	20000915		
AU 2001-90944	A3	20010914		
AU 2001-91013	A3	20010914		
AU 2001-94558	A3	20010914		
AU 2001-96871	A3	20010914		
AU 2001-96875	A3	20010914		
EP 2001-971082	A3	20010914		
US 2001-952671	A3	20010914		
US 2001-955601	A3	20010914		
EP 2001-273861	A	20011219		
EP 2001-994323	A3	20011219		
JP 2002-557938	A3	20011219		
US 2001-26966	A1	20011219		
WO 2001-US49139	W	20011219		
WO 2001-US50312	W	20011219		
WO 2001-US51031	W	20011219		
US 2001-34019	A3	20011220		
US 2001-34683	A1	20011220		
OS MARPAT 137:169539				
AB 285 Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(R6')2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6', R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6')2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared				
IT 438205-79-9P 438205-80-2P 438205-86-8P 438205-87-9P				


However, the claims pertain only to 3-(2-amino-4-pyrimidinylamino)-1H-pyrazoles, i.e. Z1 = Z2 = N, and Q = NH. I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-79-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-80-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-86-8 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-87-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:575069 CAPLUS
 DN 137:109292
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease
 IN Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Golec, Julian; Kay, David; Knegetel, Ronald; Patel, Sanjay
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 337 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 14

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002059111	A2	20020801	WO 2001-US51120	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1698627	A1	20060906	EP 2006-10798	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2432131	AA	20020801	CA 2001-2432131	20011219
CA 2432303	AA	20020829	CA 2001-2432303	20011219
WO 2002066461	A1	20020829	WO 2001-US49139	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432223	AA	20020906	CA 2001-2432223	20011219
WO 2002068415	A1	20020906	WO 2001-US50312	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003004161	A1	20030102	US 2001-26975	20011219
US 6653300	B2	20031125		
US 2003036543	A1	20030220	US 2001-25164	20011219
US 6664247	B2	20031216		
US 2003055068	A1	20030320	US 2001-26967	20011219
US 6989385	B2	20060124		

US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345926	A2	20030924	EP 2001-993360	20011219
EP 1345926	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016493	A	20030930	BR 2001-16493	20011219
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526468	A	20040326	NZ 2001-526468	20011219
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004517926	T2	20040617	JP 2002-559413	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
HU 200400842	A2	20040728	HU 2004-842	20011219
HU 200400908	A2	20040728	HU 2004-908	20011219
US 2004214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
AT 327989	E	20060615	AT 2001-271061	20011219
AT 326460	E	20060615	AT 2001-985059	20011219
AT 326461	E	20060615	AT 2001-993360	20011219
AT 326462	E	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 340172	E	20061015	AT 2001-994323	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	E	20060615	AT 2001-994347	20011220
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002670	A	20030815	NO 2003-2670	20030612
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321

AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
PRAI US 2000-257887P	P	20001221		
US 2001-286949P	P	20010427		
US 2000-232795P	P	20000915		
AU 2001-90944	A3	20010914		
AU 2001-91013	A3	20010914		
AU 2001-94558	A3	20010914		
AU 2001-96871	A3	20010914		
AU 2001-96875	A3	20010914		
EP 2001-971082	A3	20010914		
US 2001-952671	A3	20010914		
US 2001-955601	A3	20010914		
EP 2001-273861	A	20011219		
EP 2001-994323	A3	20011219		
JP 2002-557938	A3	20011219		
US 2001-26966	A1	20011219		
WO 2001-US49139	W	20011219		
WO 2001-US50312	W	20011219		
WO 2001-US51120	W	20011219		
US 2001-34019	A3	20011220		
US 2001-34683	A1	20011220		

OS MARPAT 137:109292

AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μ M: GSK-3 β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).


IT 438205-79-9P 438205-80-2P 438205-86-8P
438205-87-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-79-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-80-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-86-8 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-87-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 27 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:555487 CAPLUS
 DN 137:125169
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3
 IN Bebbington, David; Charrier, Jean-Damien; Golec, Julian; Miller, Andrew; Knegetel, Ronald
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 333 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002057259	A2	20020725	WO 2001-US49401	20011219
	WO 2002057259	A3	20030424		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP	1698627	A1	20060906	EP 2006-10798	20010914
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CA	2432129	AA	20020725	CA 2001-2432129	20011219
CA	2432303	AA	20020829	CA 2001-2432303	20011219
WO	2002066461	A1	20020829	WO 2001-US49139	20011219
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA	2432223	AA	20020906	CA 2001-2432223	20011219
WO	2002068415	A1	20020906	WO 2001-US50312	20011219
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US	2003004161	A1	20030102	US 2001-26975	20011219
US	6653300	B2	20031125		
US	2003036543	A1	20030220	US 2001-25164	20011219
US	6664247	B2	20031216		
US	2003055068	A1	20030320	US 2001-26967	20011219

US 6989385	B2	20060124		
US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1353916	A2	20031022	EP 2001-994323	20011219
EP 1353916	B1	20060920		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016411	A	20031111	BR 2001-16411	20011219
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004517894	T2	20040617	JP 2002-557938	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
HU 200400641	A2	20040628	HU 2004-641	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
HU 200400842	A2	20040728	HU 2004-842	20011219
US 2004214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
NZ 526470	A	20060331	NZ 2001-526470	20011219
AT 327989	E	20060615	AT 2001-271061	20011219
AT 326460	E	20060615	AT 2001-985059	20011219
AT 326461	E	20060615	AT 2001-993360	20011219
AT 326462	E	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 340172	E	20061015	AT 2001-994323	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	E	20060615	AT 2001-994347	20011220
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002703	A	20030819	NO 2003-2703	20030613
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321


	AU	2006201229	A1	20060413	AU	2006-201229	20060321
	AU	2006201230	A1	20060413	AU	2006-201230	20060321
	AU	2006201262	A1	20060427	AU	2006-201262	20060321
	AU	2006201263	A1	20060427	AU	2006-201263	20060321
	AU	2006201264	A1	20060427	AU	2006-201264	20060321
	AU	2006201265	A1	20060427	AU	2006-201265	20060321
	AU	2006201391	A1	20060427	AU	2006-201391	20060404
PRAI	US	2000-257887P	P	20001221			
	US	2001-286949P	P	20010427			
	US	2000-232795P	P	20000915			
	AU	2001-90944	A3	20010914			
	AU	2001-91013	A3	20010914			
	AU	2001-94558	A3	20010914			
	AU	2001-96871	A3	20010914			
	AU	2001-96875	A3	20010914			
	EP	2001-971082	A3	20010914			
	US	2001-952671	A3	20010914			
	US	2001-955601	A3	20010914			
	EP	2001-273861	A	20011219			
	EP	2001-994323	A3	20011219			
	JP	2002-557938	A3	20011219			
	US	2001-26966	A1	20011219			
	WO	2001-US49139	W	20011219			
	WO	2001-US49401	W	20011219			
	WO	2001-US50312	W	20011219			
	US	2001-34019	A3	20011220			
	US	2001-34683	A1	20011220			
OS	MARPAT	137:125169					
AB	The title compds. I	[Z1 = N, CR8; Z2 = N. CH; and at least one of Z1 and Z2 = N; Rb, Rc = TR3, LZR3; C2RbRc = (un)substituted fused (hetero)cycle; Q = NR4, O, S, etc.; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2a = R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, etc.; R = H, (un)substituted aliphatic, (hetero)aryl, heterocyclyl; R4 = R7, COR7, SO2R7, etc.; W = CO, CO2, CONR6, etc.; R6, R7 = H, alkyl; or N(R6)2 or N(R7)2 = heterocyclyl, heteroaryl] were prepared					
	For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 µM: GSK-3β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).						
IT	438205-79-9P 438205-80-2P 438205-86-8P 438205-87-9P						
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)						
	(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)						
RN	438205-79-9 CAPLUS						
CN	2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)						



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-80-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-86-8 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-87-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 28 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:487556 CAPLUS
 DN 137:47221
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease
 IN Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Everitt, Simon; Kay, David; Knegetel, Ronald; Patel, Sanjay
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 342 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050065	A2	20020627	WO 2001-US49140	20011219
	WO 2002050065	A3	20021024		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1698627	A1	20060906	EP 2006-10798	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA	2432799	AA	20020627	CA 2001-2432799	20011219
AU	2002034047	A5	20020701	AU 2002-34047	20011219
CA	2432303	AA	20020829	CA 2001-2432303	20011219
WO	2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2432223	AA	20020906	CA 2001-2432223	20011219
WO	2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	2003004161	A1	20030102	US 2001-26975	20011219
US	6653300	B2	20031125		
US	2003036543	A1	20030220	US 2001-25164	20011219
US	6664247	B2	20031216		

US 2003055068	A1	20030320	US 2001-26967	20011219
US 6989385	B2	20060124		
US 2003078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 2003105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345925	A2	20030924	EP 2001-985059	20011219
EP 1345925	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004516291	T2	20040603	JP 2002-551561	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
HU 200400639	A2	20040628	HU 2004-639	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
HU 200400842	A2	20040728	HU 2004-842	20011219
US 2004214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
NZ 526469	A	20051028	NZ 2001-526469	20011219
AT 327989	E	20060615	AT 2001-271061	20011219
AT 326460	E	20060615	AT 2001-985059	20011219
AT 326461	E	20060615	AT 2001-993360	20011219
AT 326462	E	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 340172	E	20061015	AT 2001-994323	20011219
US 2003004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 2003022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	E	20060615	AT 2001-994347	20011220
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002671	A	20030818	NO 2003-2671	20030612
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321

AU	2006201229	A1	20060413	AU	2006-201229	20060321
AU	2006201230	A1	20060413	AU	2006-201230	20060321
AU	2006201262	A1	20060427	AU	2006-201262	20060321
AU	2006201263	A1	20060427	AU	2006-201263	20060321
AU	2006201264	A1	20060427	AU	2006-201264	20060321
AU	2006201265	A1	20060427	AU	2006-201265	20060321
AU	2006201391	A1	20060427	AU	2006-201391	20060404
PRAI	US 2000-257887P	P	20001221			
	US 2001-286949P	P	20010427			
	US 2000-232795P	P	20000915			
AU	2001-90944	A3	20010914			
AU	2001-91013	A3	20010914			
AU	2001-94558	A3	20010914			
AU	2001-96871	A3	20010914			
AU	2001-96875	A3	20010914			
EP	2001-971082	A3	20010914			
US	2001-952671	A3	20010914			
US	2001-955601	A3	20010914			
EP	2001-273861	A	20011219			
EP	2001-994323	A3	20011219			
JP	2002-557938	A3	20011219			
US	2001-26966	A1	20011219			
WO	2001-US49139	W	20011219			
WO	2001-US49140	W	20011219			
WO	2001-US50312	W	20011219			
US	2001-34019	A3	20011220			
US	2001-34683	A1	20011220			

OS MARPAT 137:47221

AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20 μ M: GSK-3 β (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438205-79-9P 438205-80-2P 438205-86-8P


438205-87-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-79-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-80-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-86-8 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 438205-87-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(3-chlorophenyl)-6-(3-nitrophenyl)-N4-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 29 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:772132 CAPLUS
 DN 135:303909
 TI Preparation of aryl-substituted pyrimidines as insecticidal and acaricidal agents
 IN Wood, William Wakefield; Fleming, Linda; Cuccia, Salvatore John
 PA American Cyanamid Company, USA
 SO U.S., 11 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

Same as #33

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6306866	B1	20011023	US 1998-36490	19980306
	US 6153619	A	20001128	US 1999-273942	19990322
	US 2002045634	A1	20020418	US 2000-725376	20001129
	US 6440984	B2	20020827		
PRAI	US 1998-36490	A3	19980306		

OS MARPAT 135:303909
 AB The title compds. [I; R1, R2 = H, halo, alkyl, etc.; A = substituted Ph; B = substituted Ph; one of Y and Z = N and the other = CR2; X = O, NR; R = H, alkyl], useful for the control of insect and acarid pests (biol. data given), were prepared E.g., a 2-step synthesis of I [Y = N; Z = CH; R1 = H; X = O; A = 3-F3CC6H4; B = 3,4-Cl2C6H3] was presented.
 IT 309255-89-8P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of aryl-substituted pyrimidines as insecticidal and acaricidal agents)
 RN 309255-89-8 CAPLUS
 CN 2-Pyrimidinamine, N,4-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl-(9CI). (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:730738 CAPLUS

DN 135:288789

TI 2-Substituted 4-heteroaryl-pyrimidines with activity as inhibitors of cyclin-dependent kinases and their preparation and use in the treatment of proliferative disorders

IN Fischer, Peter Martin; Wang, Shudong

PA Cyclacel Limited, UK

SO PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072745	A1	20011004	WO 2001-GB1423	20010328
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2401748	AA	20011004	CA 2001-2401748	20010328
	GB 2361236	A1	20011017	GB 2001-7758	20010328
	GB 2361236	B2	20020424		
	EP 1274705	A1	20030115	EP 2001-915544	20010328
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	HU 200300382	A2	20030628	HU 2003-382	20010328
	JP 2003528872	T2	20030930	JP 2001-570655	20010328
	NZ 521068	A	20050429	NZ 2001-521068	20010328
	US 2002019404	A1	20020214	US 2001-823075	20010329
	US 6531479	B2	20030311		
	US 2003149057	A1	20030807	US 2002-327540	20021220
	US 6699854	B2	20040302		
PRAI	GB 2000-7636	A	20000329		
	GB 2000-15117	A	20000620		
	WO 2001-GB1423	W	20010328		
	US 2001-823075	A3	20010329		

OS MARPAT 135:288789

AB The invention relates to 2-substituted 4-heteroaryl-pyrimidines I and their pharmaceutically acceptable salts [wherein: X1 = CH and X2 = S; or 1 of X1 and X2 = S and the other = N; Z = NH, NHCO, NHSO2, NHCH2, CH2, CH2CH2, or CH:CH; R1, R2, R3 = H, alkyl, aryl, aralkyl, heterocyclyl, halo, NO2, cyano, OH, alkoxy, aryloxy, NH2, NHR', N(R')(R''), NHCOR', NH(aryl), N(aryl)2, COOH, COOR', COO(aryl), CONH2, CONHR', CON(R')(R''), CONH(aryl), CON(aryl)2, SO3H, SO2NH2, CF3, COR', or CO(aryl), wherein alkyl, aryl, aralkyl, heterocyclyl, and NH(aryl) groups may be further substituted with 1 or more halo, NO2, cyano, OH, OMe, NH2, COOH, CONH2, and/or CF3; at least 1 of R1 and R2 ≠ H when either X1 or X2 = S; R4, R5, R6, R7, R8 = H, (un)substituted alkyl, halo, NO2, cyano, OH, (un)substituted alkoxy, NH2, NHR', alkyl-aryl, alkyl-heteroaryl, NH(C:NH)NH2, N(R')3+, N(R')(R''), COOH, COOR', CONH2, CONHR', CON(R')(R''), SO3H, SO2NH2, CF3, or (CH2)nO(CH2)mNR'R'', (CH2)nCO2(CH2)mOR''' wherein n = 0, 1, 2, or 3; m = 1, 2 or 3; R', R'',

R''' = alkyl]. The invention also relates to preparation of I, pharmaceutical compns. containing them, and their use as inhibitors of cyclin-dependant kinases (CDKs), and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like. Examples include 22 syntheses and a variety of bioassays. For instance, 4-FC6H4NH2 was treated with HNO3 and cyanamide in EtOH to give 47% 4-FC6H4NHC(:NH)NH2.HNO3 (II). Sep., 5-acetyl-2,4-dimethylthiazole was condensed with N,N-dimethylformamide di-Me acetal to give 79% 3-dimethylamino-1-(2,4-dimethylthiazol-5-yl)propenone (III). Cyclocondensation of II with III in refluxing MeOCH2CH2OH in the presence of NaOH gave title compound IV in 89% yield. In an assay against multiple kinases, IV selectively inhibited CDKs, showing an IC50 of 0.019 μ M against CDK2/cyclin E, and 0.47 μ M against CDK4/cyclin D1, vs. >20 μ M against PCK α and SAPK2a. Addnl. bioassays of I showed antiproliferative and cytotoxic activity.

IT 364334-28-1P 364334-31-6P 364334-32-7P


364334-35-0P 364334-36-1P 364334-37-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroarylpyrimidines as CDK-inhibiting antiproliferative and anticancer agents)


RN 364334-28-1 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-phenyl-(9CI) (CA INDEX NAME)




RN 364334-31-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-32-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,4-dimethyl-5-thiazolyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-35-0 CAPLUS

CN 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 364334-36-1 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 364334-37-2 CAPLUS

CN Phenol, 4-[6-(2,4-dimethyl-5-thiazolyl)-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:78219 CAPLUS
 DN 134:141718
 TI Pyrimidine derivative inhibitors of viral helicase
 IN Hale, Michael; Maltais, Francois; Baker, Christopher; Janetka, James;
 Moon, Young Choon; Saunders, Jeffrey
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007027	A2	20010201	WO 2000-US19650	20000719
	WO 2001007027	A3	20010809		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-145193P	P	19990722		
	US 1999-150783P	P	19990826		

OS MARPAT 134:141718

AB A method is provided which is useful for inhibiting viral helicases, in particular the hepatitis C virus NS3 helicase. The method employs compns. including I [X = S, NR5; n = 0, 1; T = bond, linker group; R1 = R, Ph, heterocyclyl; R2 = OR, halo, SR (when dotted line indicates double bond) or R2 = :O, :S (when dotted line indicates single bond); R3 = halo, CN, CO2H, CHO, etc.; R4 = 4-chlorophenyl, 2-thienyl, cyclohexyl, etc.; R5 = H, R, OR, etc.; R = H, C3-8 cycloalkyl, (un)branched C1-12 alkyl, etc.; when dotted line indicates single bond, attached ring N substituted by R5; any N may exist as N oxide; any heteroatom may be substituted with labile group for prodrug administration]. Preferred compds. are those where R3 is an electron withdrawing group (e.g. halo, CN). More preferred are those compds. where R3 is an electron withdrawing group and R2 is OH. Most preferred are those compds. where R2 and R3 are as just described and X is S. In particular, the compns. and methods of this invention are useful in treating diseases caused by hepatitis C virus, bovine viral diarrhea virus or vaccinia virus.


IT 273920-47-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyrimidine derivative inhibitors of viral helicase)

RN 273920-47-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-(4-chlorophenyl)-2-[(4-chlorophenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:911230 CAPLUS
 DN 134:71598
 TI Preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFR kinase.
 IN Batchelor, Mark James; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive
 PA Celltech Chiroscience Limited, UK
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000078731	A1	20001228	WO 2000-GB2382	20000619
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6579983	B1	20030617	US 2000-596952	20000616
	CA 2375182	AA	20001228	CA 2000-2375182	20000619
	BR 2000011770	A	20020305	BR 2000-11770	20000619
	EP 1187816	A1	20020320	EP 2000-940569	20000619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 10084704	T	20020529	DE 2000-10084704	20000619
	GB 2369360	A1	20020529	GB 2001-30563	20000619
	HU 200201535	A2	20020828	HU 2002-1535	20000619
	JP 2003502406	T2	20030121	JP 2001-504897	20000619
	ES 2188429	A1	20030616	ES 2001-50085	20000619
	ES 2188429	B2	20050616		
	AU 778533	B2	20041209	AU 2000-55488	20000619
	BG 106116	A	20020731	BG 2001-106116	20011119
	ZA 2001009841	A	20020429	ZA 2001-9841	20011129
	NO 2001006162	A	20020218	NO 2001-6162	20011217
	US 2002147339	A1	20021010	US 2002-151518	20020520
	HK 1048815	A1	20050429	HK 2003-101022	20030212
	US 2004180914	A1	20040916	US 2004-812293	20040329
PRAI	GB 1999-14258	A	19990618		
	US 2000-596952	A1	20000616		
	WO 2000-GB2382	W	20000619		
	US 2002-151518	B1	20020520		
OS	MARPAT 134:71598				
AB	Title compds. [I; Ar = (substituted) aryl, heteroaryl; R1 = H, alkyl; R2 = X1R3; X1 = bond, linker atom or group; R3 = (substituted) aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom. group] and the salts, solvates, hydrates and N-oxides thereof, were prepared Thus, 3,4,5-trimethoxyphenylguanidinium nitrate (preparation given), 1-phenyl-2-cyano-3-dimethylaminopropen-1-one, and NaOH were refluxed in EtOH to give 5-cyano-4-phenyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine. I inhibited KDR kinase and FGFR kinase with IC50 ≤ 1 μM.				
IT	314267-54-4P 314267-59-9P 314267-61-3P				

314268-67-2P 314268-68-3P 314268-69-4P
 314268-70-7P 314268-71-8P 314268-72-9P
 314268-73-0P 314268-74-1P 314269-19-7P
 314269-20-0P 314269-21-1P 314269-23-3P
 314269-25-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFr kinase)


RN 314267-54-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[(4-fluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 314267-59-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(4-fluorophenyl)amino]-4-[4-[1-methyl-1-(1-pyrrolidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 314267-61-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[(3-fluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 314268-67-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[(3,5-difluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 314268-68-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[(3-fluoro-4-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 314268-69-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[(3,4,5-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 314268-70-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 314268-71-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[(2,4-difluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 314268-72-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[(3,4-difluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 314268-73-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[(3-chloro-4-fluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 314268-74-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 314269-19-7 CAPLUS

CN Acetamide, N-[1-[4-[5-cyano-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]phenyl]-1-methylethyl]- (9CI) (CA INDEX NAME)




RN 314269-20-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[4-[1-(dimethylamino)-1-methylethyl]phenyl]-2-[(4-fluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 314269-21-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-fluorophenyl)amino]-4-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 314269-23-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(3-chloro-4-methylphenyl)amino]-4-phenyl- (9CI) (CA INDEX NAME).



RN 314269-25-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-4-phenyl- (9CI) (CA INDEX NAME)



IT 314267-93-1P 314267-94-2P 314267-95-3P

314267-96-4P 314267-97-5P 314267-98-6P

314267-99-7P 314268-00-3P 314268-01-4P


314268-02-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-arylamino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFR kinase)


RN 314267-93-1 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[(3,5-difluorophenyl)amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 314267-94-2 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[(3-fluoro-4-methylphenyl)amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 314267-95-3 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[(3,4,5-trifluorophenyl)amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 314267-96-4 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 314267-97-5 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[(2,4-difluorophenyl)amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 314267-98-6 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[(3,4-difluorophenyl)amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 314267-99-7 CAPLUS

CN Carbamic acid, [1-[4-[2-[(3-chloro-4-fluorophenyl)amino]-5-cyano-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 314268-00-3 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[(4-fluorophenyl)amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 314268-01-4 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 314268-02-5 CAPLUS

CN Carbamic acid, [1-[4-[5-cyano-2-[[3-(3-fluorophenyl)amino]-4-pyrimidinyl]phenyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

L4 ANSWER 33 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:835377 CAPLUS
 DN 134:17494
 TI Preparation of aryl-substituted pyrimidines as insecticidal and acaricidal agents
 IN Wood, William Wakefield; Fleming, Linda; Cuccia, Salvatore John
 PA American Cyanamid Company, USA
 SO U.S., 10 pp., Division of U.S. Ser. No. 36,490.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6153619	A	20001128	US 1999-273942	19990322
	US 6306866	B1	20011023	US 1998-36490	19980306
PRAI	US 1998-36490	A3	19980306		
OS	MARPAT 134:17494				

AB The title compds. [I; R1 = H, halo, alkyl, etc.; A = substituted Ph; B = substituted Ph; with the proviso that either A or B must be substituted by at least one halogen atom; one of Y and Z = N and the other = CR2; R2 = R1; X = O, NR; R = H, alkyl], useful for the control of insect and acarid pests (biol. data given), were prepared E.g., a 2-step synthesis of I [Y = N; Z = CH; R1 = H; X = O; A = 3-F3CC6H4; B = 3,4-Cl2C6H3] was presented.

IT 309255-89-8P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aryl-substituted pyrimidines as insecticidal and acaricidal agents)

RN 309255-89-8 CAPLUS

CN 2-Pyrimidinamine, N,4-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl-
 (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:585430 CAPLUS
 DN 133:150583
 TI Preparation of phenylpyrimidine and phenyltriazine derivatives as fungicides
 IN Kumita, Izumi; Noda, Kaoru
 PA Nippon Soda Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000229949	A2	20000822	JP 1999-33002	19990210
PRAI	JP 1999-33002		19990210		

OS MARPAT 133:150583


AB Title compds. I (R1, R2 = H, halo; R3 = Ph, pyridyl, cycloalkyl, etc.; R4 = H, cyano, halo, alkyl, alkoxy, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, amino), useful as fungicides, are prepared. Thus, reaction of 1,1-bis(methylthio)-3-(2,6-dichlorophenyl)propen-3-one with 4-chlorophenylguanidine nitrate in DMF in the presence of K2CO3 gave 4-(2,6-dichlorophenyl)-2-(4-chlorophenylamino)-6-methylthiopyrimidine, reaction of which with NaBH4 in EtOH in the presence of NiCl2 and aqueous NaOH gave 4-(2,6-dichlorophenyl)-2-(4-chlorophenylamino)pyrimidine (II). II showed fungicidal activity against Botrytis cinerea.

IT 287720-02-9P 287720-04-1P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of phenylpyrimidine and phenyltriazine derivs. as fungicides)


RN 287720-02-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,6-dichlorophenyl)-6-(methylthio)-(9CI) (CA INDEX NAME)




RN 287720-04-1 CAPLUS


CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,6-dichlorophenyl)-6-(methylsulfonyl)-(9CI) (CA INDEX NAME)



IT 287720-03-0P 287720-05-2P 287720-06-3P
 287720-08-5P 287720-09-6P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except
 adverse); BSU (Biological study, unclassified); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylpyrimidine and phenyltriazine derivs. as fungicides)
 RN 287720-03-0 CAPLUS
 CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,6-dichlorophenyl)- (9CI) (CA
 INDEX NAME)




RN 287720-05-2 CAPLUS
 CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2,6-dichlorophenyl)-6-methoxy-
 (9CI) (CA INDEX NAME)




RN 287720-06-3 CAPLUS

CN 4-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)amino]-6-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)




RN 287720-08-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[(4-chlorophenyl)amino]-6-(2,6-dichlorophenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 287720-09-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-chlorophenyl)-6-(2,6-dichlorophenyl)-N4,N4-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:513679 CAPLUS
 DN 133:120681
 TI Preparation of amino acid acyl derivatives as inhibitors of leukocyte
 adhesion mediated by VLA-4
 IN Konradi, Andrei; Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan;
 Welmaker, Gregory S.; Kreft, Anthony; Sarantakis, Dimitrios; Dressen,
 Darren B.; Grant, Francine S.; Semko, Christopher; Xu, Ying-Zi
 PA Elan Pharmaceuticals, Inc., USA; American Home Products
 SO PCT Int. Appl., 342 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000043372	A1	20000727	WO 2000-US1686	20000121
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359115	AA	20000727	CA 2000-2359115	20000121
	EP 1144388	A1	20011017	EP 2000-913245	20000121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000007663	A	20020507	BR 2000-7663	20000121
	US 6479492	B1	20021112	US 2000-489378	20000121
	US 6492372	B1	20021210	US 2000-489377	20000121
	HU 200201213	A2	20021228	HU 2002-1213	20000121
	AU 773538	B2	20040527	AU 2000-34724	20000121
	TW 239954	B1	20050921	TW 2000-89101088	20000124
	ZA 2001005314	A	20030327	ZA 2001-5314	20010627
	NO 2001003600	A	20010920	NO 2001-3600	20010720
	US 2003125324	A1	20030703	US 2002-218366	20020815
	US 6911439	B2	20050628		
	US 2003144328	A1	20030731	US 2002-218445	20020815
	US 6903088	B2	20050607		
	US 2003139402	A1	20030724	US 2002-251442	20020920
	US 7049306	B2	20060523		
	HK 1046132	A1	20060504	HK 2002-107038	20020926
	NZ 529822	A	20031219	NZ 2003-529822	20031127
	US 2004147512	A1	20040729	US 2003-748089	20031229
	US 7005433	B2	20060228		
	US 2005203093	A1	20050915	US 2005-33079	20050110
	US 2005261293	A1	20051124	US 2005-145489	20050602
PRAI	US 1999-116923P	A2	19990122		
	US 1999-160999P	P	19991021		
	US 1999-160199P	P	19991019		
	US 2000-489377	A3	20000121		
	US 2000-489378	A3	20000121		
	WO 2000-US1686	W	20000121		
	US 2002-218366	A3	20020815		
	US 2002-218445	A3	20020815		
	US 2002-251442	A1	20020920		

OS MARPAT 133:120681

AB Disclosed are compds. $R_2-W:CR_1-Q-CR_3R_3'COX$ and $R_2-W'-CHR_1-Q-CR_3R_3'COX$ [R_1 and R_2 are joined to form a ring; $R_3, R_3' = H, \text{iso-Pr}, -CH_2Z$ or $:CHZ$, where $Z = H, \text{acylamino}, \text{alkyl}, \text{alkoxy}, \text{aryloxy}, \text{aryl}, \text{aryloxyaryl}, \text{carboxy}, \text{carboxyalkyl}, \text{etc.}$; $Q = O, S, SO, SO_2, NH$ or imino group; $W = \text{nitrogen}, \text{carbon}$; $W' = \text{nitrogen}, \text{carbon}, \text{oxygen}, \text{sulfur}, SO, SO_2$; $X = OH, (\text{un})\text{substituted alkoxy}, \text{alkenoxy}, \text{cycloalkoxy}, \text{cycloalkenoxy}, \text{aryloxy}, \text{heteroaryloxy}$ or heterocyclyloxy, an amino group] which bind VLA-4. Thus, N-[5-(N-4-toluenesulfonylamino)pyrimidin-4-yl]-L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester was prepared by condensation of L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester with 2,4-dichloro-5-nitropyrimidine, followed by nitro group reduction and tosylation. Compds. synthesized in the examples are expected to have a binding affinity to VLA-4 expressed by an IC_{50} of 15 μM or less.

IT 285139-65-3P 285140-62-7P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid acyl derivs. as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 285139-65-3 CAPLUS

CN L-Tyrosine, N-[2-[(4-chlorophenyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-62-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, α -[[2-[(4-chlorophenyl)methylamino]-5-(2,4,6-trimethylphenyl)-4-pyrimidinyl]amino]-2',6'-dimethoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:495258 CAPLUS
 DN 131:129907
 TI Preparation and formulation of tricyclic compounds as immunosuppressants and allergy inhibitors
 IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiro
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 298 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938829	A1	19990805	WO 1999-JP297	19990126
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2318368	AA	19990805	CA 1999-2318368	19990126
	AU 9919837	A1	19990816	AU 1999-19837	19990126
	AU 742641	B2	20020110		
	EP 1052238	A1	20001115	EP 1999-900676	19990126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9908539	A	20001205	BR 1999-8539	19990126
	TR 200002225	T2	20001221	TR 2000-200002225	19990126
	HU 200103304	A2	20020228	HU 2001-3304	19990126
	NZ 506101	A	20030630	NZ 1999-506101	19990126
	RU 2216533	C2	20031120	RU 2000-121556	19990126
	NO 2000003706	A	20000914	NO 2000-3706	20000719
	US 6562817	B1	20030513	US 2000-600790	20000721
PRAI	JP 1998-15554	A	19980128		
	WO 1999-JP297	W	19990126		

OS MARPAT 131:129907


AB The title compds. I [each of ring A, ring B and ring C is independently a substituted or unsubstituted aromatic ring or a substituted or unsubstituted five or six-membered heterocycle which may be condensed with a benzene ring; when ring A, ring B and/or ring C is a substituted or unsubstituted five-membered heterocycle, W1, W2 and/or W3 represents a bond; X is O or NR1 (where R1 is hydrogen, a lower alkyl or the like); Y is hydrogen, a lower alkyl, a lower alkenyl or the like; one of V1 and V2 is a single bond and the other is a single bond, O, etc.] are prepared The title compound II in vitro showed IC50 of 400 ng/mL against the growth of mouse EL4 cells. The inhibiting activities of compds. of this invention against the production of IgE were also demonstrated.

IT 234429-03-9P 234429-04-0P 234429-05-1P
 234429-06-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tricyclic compds. as immunosuppressants and allergy inhibitors)


RN 234429-03-9 CAPLUS

CN Phenol, 5-[2-[(4-fluorophenyl)amino]-4-methoxy-6-methyl-5-pyrimidinyl]-2-[(4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 234429-04-0 CAPLUS

CN Phenol, 5-[2-[(4-fluorophenyl)amino]-4-methoxy-6-methyl-5-pyrimidinyl]-2-[(4-methylphenyl)methoxy]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 234429-05-1 CAPLUS

CN Phenol, 5-[2-[(4-fluorophenyl)amino]-4-methoxy-6-methyl-5-pyrimidinyl]-2-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)




RN 234429-06-2 CAPLUS

CN Phenol, 5-[2-[(4-fluorophenyl)amino]-4-methoxy-6-methyl-5-pyrimidinyl]-2-[(3-methyl-2-butenyl)oxy]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)




RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:295954 CAPLUS
 DN 131:5238
 TI 4-Aryl-2-anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists
 AU Cocuzza, Anthony J.; Hobbs, Frank W.; Arnold, Charles R.; Chidester, Dennis R.; Yarem, Jerry A.; Culp, Steven; Fitzgerald, Lawrence; Gilligan, Paul J.
 CS Chemical and Physical Sciences Department, DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(7), 1057-1062
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB A series of 4-aryl-2-(N-ethylanilino)pyrimidines has been synthesized as corticotropin-releasing hormone inhibitors. The effect of substitution on each aromatic ring on receptor binding was investigated.
 IT 219840-42-3P 219840-43-4P 219840-45-6P
 219840-46-7P 219840-47-8P 219840-48-9P
 219840-49-0P 219840-50-3P 219840-51-4P
 219840-52-5P 219840-53-6P 219840-54-7P
 219840-55-8P 219840-56-9P 219840-57-0P
 219840-59-2P 219840-60-5P 219840-61-6P
 219840-62-7P 219840-63-8P 219840-64-9P
 219840-65-0P 219840-82-1P 219840-83-2P
 225922-77-0P 225922-78-1P 225922-79-2P
 225922-80-5P 225922-83-8P 225922-84-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (2-anilino-4-arylpyrimidines as corticotropin-releasing hormone antagonists)
 RN 219840-42-3 CAPLUS
 CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-(2-bromophenyl)-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-43-4 CAPLUS
 CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-(2-chlorophenyl)-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-45-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-46-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 219840-47-8 CAPLUS


CN 1,4-Benzenediamine, 2-bromo-N1-ethyl-6-methoxy-N4,N4-dimethyl-N1-[4-methyl-6-[2-(trifluoromethyl)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 219840-48-9 CAPLUS


CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-

[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-49-0 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-50-3 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-(2-fluorophenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-51-4 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-4-(2-chlorophenyl)-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-52-5 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 219840-53-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-aminophenyl)-N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-54-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-[2-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-55-8 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-[2-(dimethylamino)phenyl]-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-56-9 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dibromophenyl)-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-57-0 CAPLUS

CN Ethanone, 1-[3-bromo-4-[ethyl[4-methyl-6-[2-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 219840-59-2 CAPLUS


CN Benzonitrile, 2-[2-[[2-bromo-4-(1-methylethyl)phenyl]ethylamino]-6-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 219840-60-5 CAPLUS


CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-

[2-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-61-6 CAPLUS

CN Benzoic acid, 2-[2-[[2-bromo-4-(1-methylethyl)phenyl]ethylamino]-6-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 219840-62-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(methylthio)phenyl]-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-63-8 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(methylsulfonyl)phenyl]-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-64-9 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-(2-methoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-65-0 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 219840-82-1 CAPLUS


CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 219840-83-2 CAPLUS


CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-(2,6-

dichlorophenyl)-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 225922-77-0 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 225922-78-1 CAPLUS

CN 2-Pyrimidinamine, 4-[1,1'-biphenyl]-2-yl-N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 225922-79-2 CAPLUS

CN 2-Pyrimidinamine, 4-[1,1'-biphenyl]-3-yl-N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 225922-80-5 CAPLUS

CN 2-Pyrimidinamine, 4-[1,1'-biphenyl]-4-yl-N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 225922-83-8 CAPLUS

CN Benzenaminium, 2-[2-[[2-bromo-4-(1-methylethyl)phenyl]ethylamino]-6-methyl-4-pyrimidinyl]-N,N,N-trimethyl-, salt with trifluoromethanesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 225922-82-7


CMF C25 H32 Br N4



CM 2


CRN 37181-39-8

CMF C F3 O3 S



RN 225922-84-9 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD.
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:48709 CAPLUS
 DN 130:125084
 TI Aryl- and arylamino-substituted heterocycles as corticotropin releasing hormone (CRF) antagonists
 IN Cocuzza, Anthony J.; Hobbs, Frank W.; Beck, James P.; Gilligan, Paul J.
 PA Du Pont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901439	A1	19990114	WO 1998-US13840	19980702
	W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2296014	AA	19990114	CA 1998-2296014	19980702
	AU 9881810	A1	19990125	AU 1998-81810	19980702
	EP 994860	A1	20000426	EP 1998-931783	19980702
	R: CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	US 6103737	A	20000815	US 1998-109395	19980702
	JP 2002510322	T2	20020402	JP 1999-507408	19980702
PRAI	US 1997-51745P	P	19970703		
	WO 1998-US13840	W	19980702		

OS MARPAT 130:125084

AB Corticotropin releasing factor (CRF) antagonists I and their stereoisomers and pharmaceutically acceptable salts are disclosed [wherein Y = CR2 or N; Z = CH or N; K = CR5 or N; R1 = alk(en/yn)yl, Cl, F, cyano, CF3; R2R4 = E-F where E and F = CR9 and/or CR9'; or R2R4 = A:D where A and D = CH, CR10, or N, provided that A:D is oriented to form imidazole but not pyrazole; or R2R4 = A-D where A = NR9 and D = CO, oriented to form an imidazolone; R3 = Ph, naphthyl, pyridinyl, or pyrimidinyl, all substituted by R8; R4 = (un)substituted alkyl, allyl, or propargyl; R5 = 1-4 of alk(en/yn)yl, cycloalkyl, halo, NO2, cyano, NR6R7, OR7, COR7, C(:NOR9)R7, SONR7, etc.; or 2 R5 moieties may form CR9R9'CR9R9'O, CR9:CR9'O, etc.; R6, R7 = H or (un)substituted alkyl, cycloalkyl, (CH2)mPh or (CH2)m-heteroaryl; R8 = alk(en/yn)yl, cycloalkyl, Ph, heteroaryl, halo, NO2, cyano, NR6R7, OR7, etc., with provisos; R9, R9' = H, alkyl; n = 0-2; m = 0-6]. Also disclosed is their use in treating psychiatric disorders and neurol. diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders, as well as treatment of immunol., cardiovascular or heart-related diseases, and colonic hypersensitivity associated with psychopathol. disturbance and stress in mammals. For example, condensation of 2-BrC6H4COCH3 with MeC(OMe)2NMe2 gave 2-BrC6H4COCH:MeNMe2, which underwent cyclocondensation with (2-bromo-4-isopropylphenyl)guanidine-HCl, followed by N-alkylation of the resultant aminopyrimidine with EtI and NaH in DMSO, to give title compound II. Some I were active (no data). in an assay for inhibition of CRF-stimulated adenylate cyclase activity.

IT 219840-85-4P 219840-87-6P 219840-90-1P
 219840-92-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aryl-and arylamino-substituted heterocycles as

corticotropin releasing hormone antagonists)


RN 219840-85-4 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-(2-bromophenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-87-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-90-1 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-4-(2-methoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 219840-92-3 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-methyl-6-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




IT 219840-42-3P 219840-43-4P 219840-44-5P
 219840-45-6P 219840-46-7P 219840-47-8P
 219840-48-9P 219840-49-0P 219840-50-3P
 219840-51-4P 219840-52-5P 219840-53-6P
 219840-54-7P 219840-55-8P 219840-56-9P
 219840-57-0P 219840-59-2P 219840-60-5P
 219840-61-6P 219840-62-7P 219840-63-8P
 219840-64-9P 219840-65-0P 219840-66-1P
 219840-67-2P 219840-82-1P 219840-83-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of aryl- and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists)


RN 219840-42-3 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-(2-bromophenyl)-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-43-4 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-(2-chlorophenyl)-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-44-5 CAPLUS

CN 1,4-Benzenediamine, 2-bromo-N1-[4-(2-chlorophenyl)-6-methyl-2-pyrimidinyl]-N1-ethyl-6-methoxy-N4,N4-dimethyl- (9CI) (CA INDEX NAME)




RN 219840-45-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 219840-46-7 CAPLUS


CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 219840-47-8 CAPLUS


CN 1,4-Benzenediamine, 2-bromo-N1-ethyl-6-methoxy-N4,N4-dimethyl-N1-[4-methyl-

6-[2-(trifluoromethyl)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 219840-48-9 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-49-0 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-50-3 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-(2-fluorophenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-51-4 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-4-(2-chlorophenyl)-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-52-5 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 219840-53-6 CAPLUS

CN 2-Pyrimidinamine, 4-(2-aminophenyl)-N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-54-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-[2-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-55-8 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-[2-(dimethylamino)phenyl]-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)




RN 219840-56-9 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dibromophenyl)-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 219840-57-0 CAPLUS


CN Ethanone, 1-[3-bromo-4-[ethyl[4-methyl-6-[2-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]phenyl]-2-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 219840-59-2 CAPLUS


CN Benzonitrile, 2-[2-[[2-bromo-4-(1-methylethyl)phenyl]ethylamino]-6-methyl-

4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 219840-60-5 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-[2-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-61-6 CAPLUS

CN Benzoic acid, 2-[2-[[2-bromo-4-(1-methylethyl)phenyl]ethylamino]-6-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 219840-62-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(methylthio)phenyl]-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-63-8 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(methylsulfonyl)phenyl]-N-ethyl-4-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-64-9 CAPLUS

CN 2-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-(2-methoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 219840-65-0 CAPLUS


CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 219840-66-1 CAPLUS


CN 2-Pyrimidinamine, N-(2,4-dibromophenyl)-N-ethyl-4-methyl-6-[2-

(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-67-2 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dibromophenyl)-N-ethyl-4-methyl-6-[2-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-82-1 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-N-ethyl-4-methyl-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 219840-83-2 CAPLUS

CN 2-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-4-(2,6-dichlorophenyl)-N-ethyl-6-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 39 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:394334 CAPLUS
 DN 129:67791
 TI Preparation of 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidines
 and related compounds as drugs
 IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
 PA Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
 SO PCT Int. Appl., 232 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824782	A2	19980611	WO 1997-US22390	19971204
	WO 9824782	A3	19980827		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	ZA 9710727	A	19980612	ZA 1997-10727	19971128
	CA 2274063	AA	19980611	CA 1997-2274063	19971204
	AU 9860120	A1	19980629	AU 1998-60120	19971204
	AU 733877	B2	20010531		
	EP 948497	A2	19991013	EP 1997-954778	19971204
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9713850	A	20000229	BR 1997-13850	19971204
	CN 1246858	A	20000308	CN 1997-181563	19971204
	HU 200001698	A2	20010428	HU 2000-1698	19971204
	NZ 335997	A	20010831	NZ 1997-335997	19971204
	JP 2002514195	T2	20020514	JP 1998-525850	19971204
	TW 520362	B	20030211	TW 1997-86118244	19971204
	EP 1314731	A2	20030528	EP 2002-27704	19971204
	EP 1314731	A3	20040102		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL			
	EP 1314732	A2	20030528	EP 2002-27705	19971204
	EP 1314732	A3	20040102		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL			
	CZ 296911	B6	20060712	CZ 1999-2015	19971204
	ZA 9710911	A	19980605	ZA 1997-10911	19971205
	MX 9905168	A	20000228	MX 1999-5168	19990603
	US 6410729	B1	20020625	US 2000-598740	20000621
	US 2003069425	A1	20030410	US 2002-117552	20020403
	US 6610698	B2	20030826		
PRAI	US 1996-32128P	P	19961205		
	US 1997-50950P	P	19970613		
	US 1997-976054	A	19971121		
	EP 1997-954778	A3	19971204		
	US 1997-984774	B1	19971204		
	WO 1997-US22390	W	19971204		
	US 2000-598740	A3	20000621		

OS MARPAT 129:67791

AB Novel pyrimidines [I; R1, R2 = ZY, with a proviso; Z = bond, (un)substituted alk(en)yl, alkynyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl; etc; Y = H, halo, NO2, COR20, CNR5NR5R21, OR21, O2CR21, etc.; R5 = H, (un)substituted alk(en)yl, alkynyl, cycloalkyl, (hetero)aryl, etc.; R20 = (un)substituted alk(en)yl, alkynyl, aralkoxy, aralkylthio, aralkylsulfonyl, etc.; R21 = H, any of definitions for R20] and their pharmaceutically acceptable salts, effective for prophylaxis and treatment of diseases mediated by tumor necrosis factor α (TNF- α), IL-1 β , IL-6 and/or IL-8 and other maladies, e.g., pain and diabetes, were prepared, e.g., by enamination of 2-(4-fluorophenyl)-1-(4-pyridinyl)ethanone (II) with (Me2N)2CHOMe and cyclocondensation of the resulting (dimethylamino)propenone with an amidine, guanidine or urea. I analogs, prodrugs, pharmaceutical compns., methods for prophylaxis and treatment of diseases or conditions involving inflammation, pain, diabetes, etc., and processes for making such compds. and their intermediates are also claimed. For example, heating a mixture of II with (Me2N)2CHOMe at 110° for 1.5 h under Ar gave 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridyl)-3-propen-1-one which was cyclocondensed with 4-pyridylamidine (prepared in situ from pyridylamidine-HCl and Na) by refluxing in EtOH to give a title compound I (R1 = R12 = 4-pyridinyl, R2 = H, R11 = 4-FC6H4). The latter in mice inhibited lipopolysaccharide-induced TNF- α release with IC50 ≤ 20 μ M.


IT 208935-17-5P 208935-23-3P 208935-27-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-substituted (fluorophenyl)(pyridyl)pyrimidines and related compds. as drugs)


RN 208935-17-5 CAPLUS

CN 2-Pyrimidinamine, N-(2,6-dichlorophenyl)-5-(4-fluorophenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 208935-23-3 CAPLUS

CN 2-Pyrimidinamine, N,5-bis(4-fluorophenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 208935-27-7 CAPLUS

CN 2-Pyrimidinamine, 5-(4-fluorophenyl)-4-(4-pyridinyl)-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:465572 CAPLUS
 DN 125:221772
 TI Fused cyanopyrimidines. Part II. Synthesis and reactions of fused cyanopyrimidine derivatives as affecting enzymic agents
 AU Abdel-Aziz, S. A.; Allimony, H. A.; El-Shaaer, H. M.; Ali, Usama F.; Abdel-Rahman, R. M.
 CS Fac. Educ., Ain-Shams Univ., Cairo, Egypt
 SO Phosphorus, Sulfur and Silicon and the Related Elements (1996), 113(1-4), 67-77
 CODEN: PSSLEC; ISSN: 1042-6507
 PB Gordon & Breach
 DT Journal
 LA English
 AB Some new fused heterobicyclic systems, such as thiazolo[3,2-a]pyrimidin-5-one (I; R = Ph, X = S, X1 = CH), 2,3-tetrahydrothiazolo[3,2-a]pyrimidin-5-one (II; X2 = S), 2,4-tetrahydrothiazino[3,2-a]pyrimidin-3,6-dione (III; Y = Y2 = H, H, Y1 = O), 3-hydrothiazino[3,2-a]pyrimidin-2,4,6-trione (III; Y = Y2 = O, Y1 = H, H), 3-arylidene-thiazino[3,2-a]pyrimidin-2,4,6-trione (III; Y = Y2 = O, Y1 = CHC6H4Cl-4) and/or the related nitrogen compds. such as 2,3-tetrahydroimidazolo[3,2-a]pyrimidin-5-one (II; X2 = NH), 1-aryl-2,3-tetrahydroimidazolo[3,2-a]pyrimidin-5-one (II; X2 = NC6H4Cl-4), quinazolino[3,2-a]pyrimidin-6,8-dione (IV) and 3-mercapto-1,2,4-triazolo[4,3-a]pyrimidin-5-one (I; R = SH, X = NH, X1 = N) have been synthesized by the interaction of 2-mercapto-4-arylidene-5-cyanopyrimidin-6(1H)-one (V) with α,β -bifunctional nitrogen, oxygen and/or sulfur compds. The structures have been characterized by elemental analyses, IR, UV, ¹H NMR and mass spectra data. Some newly prepared compds. revealed a moderate effect on the activity of cellobiase produced by *Aspergillus nidulans*.
 IT 181175-85-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and reactions of fused cyanopyrimidine derivs. as affecting enzymic agent)
 RN 181175-85-9 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)amino]-6-(2,4-dichlorophenyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 41 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1990:478409 CAPLUS
 DN 113:78409
 TI (Morpholinocarbonyl)benzothiophenes and analogs as agrochemical fungicides
 and their preparation
 IN Pepin, Regis; Schmitz, Christian; Lacroix, Guy Bernard; Dellis, Philippe;
 Veyrat, Christine
 PA Rhone-Poulenc Agrochimie, Fr.
 SO Eur. Pat. Appl., 75 pp.
 CODEN: EPXXDW
 DT Patent
 LA French
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 360701	A1	19900328	EP 1989-420320	19890831
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FR 2635776	A1	19900302	FR 1988-11665	19880901
	FR 2635776	B1	19930611		
	FR 2648459	A1	19901221	FR 1989-5774	19890425
	FR 2648459	B1	19940527		
	FR 2649107	A1	19910104	FR 1989-9150	19890703
	FR 2649107	B1	19940819		
	FR 2649699	A1	19910118	FR 1989-9742	19890713
	HU 207931	B	19930728	HU 1989-4523	19890831
PRAI	FR 1988-11665	A	19880901		
	FR 1989-5774	A	19890425		
	FR 1989-9150	A	19890703		
	FR 1989-9742	A	19890713		

OS CASREACT 113:78409; MARPAT 113:78409

AB The title compds. I [ring A is a (substituted) C or heterocyclic ring containing ≥ 1 unsatd. bond, such as ethylene or aromatic; Y = O, S; Z = NR₁R₂; R₁, R₂ = (substituted) alkyl, alkoxy, C3-7 cycloalkyl, alkenyl, C3-7 alkynyl; or NR₁R₂ = (un)saturated (substituted) heterocyclyl; R₃-R₅ = H, halo, (substituted) amino, (substituted) alkyl, alkoxy, etc.; R₃ and R₄ (in meta and para positions) together may form a single radical containing 1 or 2 O atoms] were prepared A mixture of benzothiophene II (R = NH₂) and NaNO₂ in H₂O containing H₂SO₄ was stirred for 1 h and then mixed with aqueous


KI. The resulting mixture was heated at 60° for 1 h to give II (R = iodo). At 1000 ppm, 69 compds. I [e.g. II (R = NO₂)] gave 80% inhibition of Phythophthora infestans.

IT 128568-04-7P 128568-05-8P 128568-06-9P
 128568-07-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as agrochem. fungicide)


RN 128568-04-7 CAPLUS

CN Morpholine, 4-[[2-[(4-chlorophenyl)amino]-4-(3,4-dimethoxyphenyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 128568-05-8 CAPLUS

CN Morpholine, 4-[[2-[(3,4-dichlorophenyl)amino]-4-(3,4-dimethoxyphenyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 128568-06-9 CAPLUS

CN Morpholine, 4-[[2-[(4-bromo-2-chlorophenyl)amino]-4-(3,4-dimethoxyphenyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 128568-07-0 CAPLUS

CN Morpholine, 4-[[2-[(3-chloro-4-fluorophenyl)amino]-4-(3,4-dimethoxyphenyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1986:186441 CAPLUS
 DN 104:186441
 TI Pharmaceutically useful pyrimidines
 IN Hashimoto, Masashi; Robinson, David Hulme
 PA Fisons PLC, UK
 SO Eur. Pat. Appl., 42 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 164204	A1	19851211	EP 1985-302902	19850425
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DK 8502039	A	19851113	DK 1985-2039	19850508
	FI 8501837	A	19851113	FI 1985-1837	19850509
	ZA 8503522	A	19860326	ZA 1985-3522	19850509
	NO 8501877	A	19851113	NO 1985-1877	19850510
	AU 8542276	A1	19851114	AU 1985-42276	19850510
	JP 60246377	A2	19851206	JP 1985-98167	19850510
	ES 543047	A1	19860716	ES 1985-543047	19850510
	CN 85103378	A	19860709	CN 1985-103378	19850514
PRAI	GB 1984-12184	A	19840512		
	GB 1985-417	A	19850108		
	EP 1985-302902	A	19850425		

OS MARPAT 104:186441


AB The title compds. [I; RR6 or R3R6 = bond; R = H, alkyl, aralkyl, Ph, alkanoyl; R1 = (un)substituted Ph, pyridinyl, pyrimidinyl, thiazolyl, pyrazinyl, pyridazinyl, imidazolyl; R2, R4, R5 = H, alkyl, alkoxy, OH, R1; R3 = H, alkyl, aralkyl, Ph; R2R4, R2R5 = CH:CHCH:CH] were prepared by cyclocondensation of RR1C(:NR3)NH2 (II) with ZR5C:CR2COR4 (III, Z = leaving group). Thus, 10.0 g II.(HO)2CO (R = Ph, R1 = R3 = H) and 10.0 g III (R2 = 4-MeOC6H4, R4 = R5 = H, Z = Me2N) were refluxed 17 h in pyridine to give 5.4 g pyrimidinamine IV. In mice I restore immune response depressed by presence of implanted Lewis lung sarcoma or by administration of cyclophosphamide.

IT 101987-04-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as immune adjuvant)

RN 101987-04-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dichlorophenyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 43 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1970:55485 CAPLUS
 DN 72:55485
 TI Antiinflammatory 2-anilino-5-methyl-6-phenylpyrimidines
 IN Wagner, Hans A.
 PA G.D. Searle and Co.
 SO U.S., 3 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3481932	A	19691202	US 1967-664911	19670901
PRAI	US 1967-664911	A	19670901		

AB The title compds. (I) useful as antihypercholes-teremics, as antiprotozoal, and antiinflammatory agents, are prepared Thus, a mixture of 246 g 2-ethylthio-5-methyl-6-phenyl-4-pyrimidinol and 93 g PhNH₂ in 1000 g Cellosolve was refluxed for 48 hr to give 2-anilino-5-methyl-6-phenyl-4-pyrimidinol (II). A mixture of 15 g II and 70 g POCl₃ was refluxed 40 min to give 2-anilino-4-chloro-5-methyl-6-phenylpyrimidine. I (X = H, Z = Cl) (III). A solution of 100 g III and 26 g NaN₃ in 700 cc Me₂CO was stirred 5 hr at 70-80° to give I (X = H, Z = N₃) (IV). A mixture of 1 g 5% Pd/C, 5 g IV and 100 g dioxane was stirred with H at 1 atm at room temp 18 hr to give I (X = H, Z = NH₂). The following I were similarly prepared using a substituted aniline (X and Z, given): 2-F, Cl; 4-Cl, Cl (m. 183-4°); 4-Cl, N₃ (m. 129-30°); 3-Br, Cl; 4-I, Cl; Cl, NH₂ (m. 159-61°).

IT 26487-70-7P 26487-71-8P 26487-72-9P
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (manufacture and pharmacological activity of)


RN 26487-70-7 CAPLUS

CN Pyrimidine, 4-chloro-2-(p-chloroanilino)-5-methyl-6-phenyl- (8CI) (CA INDEX NAME)




RN 26487-71-8 CAPLUS

CN Pyrimidine, 4-azido-2-(p-chloroanilino)-5-methyl-6-phenyl- (8CI) (CA INDEX NAME)




RN 26487-72-9 CAPLUS

CN Pyrimidine, 4-amino-2-(p-chloroanilino)-5-methyl-6-phenyl- (8CI) (CA
INDEX NAME)




L4 ANSWER 44 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1956:57198 CAPLUS
 DN 50:57198
 OREF 50:10801d-i
 TI 4-Hydroxy-5-alkyl-6-phenylpyrimidine derivatives
 IN Rorig, Kurt J.; Nicholson, Robert T.
 PA G.D. Searle and Co.
 DT Patent
 LA Unavailable
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2740785		19560403	US 1954-436992	19540615
AB	<p>6,5,4,2-ArR''(HO)(RR'N)-tetrasubstd. pyrimidines where Ar is a lower aryl radical, R is a lower alkyl, aryl, haloaryl, or lower alkylcarbonyl radical, R' is H or a lower alkyl radical, and R'' is a lower alkyl were prepared. The compds. are diuretics and bacteriostatic agents. [H2NC(:NH)NH2].H2CO3 (I) (170), MeCHBzCO2Et (II) 325, and EtOH 1000 parts refluxed 12 h., then kept 24 h. at 0°, and the precipitate filtered off (the filtrate on concentration furnished addnl. material) afforded 2-amino-5-methyl-6-phenyl-4-pyrimidinol (III) (HCl salt, m. 225-7°). III 30 and fused NaOAc 60 ground to a fine powder, treated with Ac2O 195, the mixture stirred and refluxed 3 h., stirred with cold water 2000 parts, and the resulting precipitate filtered off and washed with water gave the 2-AcHN analog, m. 289-90°. Similarly, from II, H2NCSNH2 (IV), Na, and EtOH was obtained the 2-HS analog of III, m. 236-7° (from dilute EtOH), which on alkylation (EtBr, Na, EtOH) gave the 2-EtS compound (V), m. 192-3°. V with Me2NH and EtOH heated 16 h. at 150° in a rocking bomb gave the 2-Me2N analog of III, white needles, m. 258-9°. III refluxed with POCl3 gave the 4-Cl compound (VI), prisms, m. 131-2.5° (from EtOH), which with alc. NaHS afforded the 4-HS compound (VII), m. 270-4° (decomposition). VII with Ac2O and pyridine gave the 2-AcNH compound, m. 241-4°. I and BuCHBzCO2H yielded 2-amino-5-butyl-6-phenyl-4-pyrimidinol, m. 300-2° (decomposition), which after treatment with EtCO2Na and (EtCO)2O gave the 2-EtCONH analog, colorless, high-melting. 2,5-Me2C6H3CHMeCO2Et, IV, and Na in EtOH stirred and refluxed 8 h. furnished 2-mercapto-5-methyl-6-(2,5-dimethylphenyl)-4-pyrimidinol (VIII). VIII with EtBr, EtOH, and Na gave the 2-EtS compound which with Et2NH in EtOH after shaking in a bomb 16 h. at 150° afforded the 2-Et2N compound, white prisms, recrystd. from EtOCH2CH2OH (IX). V refluxed 50 h. with PhNH2 in IX gave the 2-PhNH compound, crystalline precipitate; 2-p-ClC6H4NH analog, m. 265-6.5° (with prior sintering at 260° (from EtOH)).</p>				
IT	500692-27-3, 4-Pyrimidinol, 2-p-chloroanilino-5-methyl-6-phenyl- (preparation of)				
RN	500692-27-3 CAPLUS				
CN	4(1H)-Pyrimidinone, 2-[(4-chlorophenyl)amino]-5-methyl-6-phenyl- (9CI) (CA INDEX NAME)				



L4 ANSWER 45 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1948:8848 CAPLUS
 DN 42:8848
 OREF 42:1972c-f
 TI 4-Hydroxypyrimidine derivatives
 IN Curd, Francis H. S.; Raison, Clifford G.; Rose, Francis L.
 PA Imperial Chemical Industries Ltd.
 DT Patent
 LA Unavailable
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2433439		19471230	US	
AB	<p>The compds. are prepared by heating in EtOCH₂CH₂OH the appropriate arylamine and a 4-hydroxypyrimidine substituted in the 6-position by a hydrocarbon radical and in the 2-position by an alkylmercapto or substituted alkylmercapto group. The preparation of the following 2-derivs. of 4-hydroxy-6-methylpyrimidine is described: p-chloroanilino, colorless thick laminas, m. 294°; p-methoxyanilino, m. 212-13°; p-ethoxyanilino, m. 187-9°; p-bromoanilino, m. 284-6°; p-butylanilino, m. 195-6°; p-carbomethoxyanilino, m. 274-6°; p-phenyl-anilino, m. 258-9°; p-cyanoanilino, m. 330°; (2-naphthylamino), colorless needles, m. 243-5°; (1-naphthylamino), m. 256-7°; (4-chloro-1-naphthylamino), m. 298-301°; (6-bromo-2-naphthylamino), colorless crystals, m. 286-8°; (6-methoxy-2-naphthylamino), colorless crystals, m. 238-9°; (2,4-dichloroanilino), m. 278-80°; (3,4-dichloroanilino), m. 250-2°; (2,5-dichloroanilino), m. 244-6°; (2-methyl-4-chloroanilino), m. 252-4°; (3-chloro-4-methylanilino), m. 252-4°; (3-chloroanilino), m. 227-9°; (2-chloroanilino), m. 244-6°; anilino, m. 244-6°; (3,4-dimethylanilino), m. 238-9°; (3,5-dimethylanilino), m. 268°; (3,5-dibromoanilino), almost colorless needles, m. 325°; (2-methoxyanilino), colorless needles, m. 245-6°; (2-methylanilino), m. 204°; (3-methylanilino), m. 212-13°; (4-dimethyl-aminoanilino), m. 240-2°; p-toluidino, colorless crystals, m. 230°; (p-methylmercaptoanilino), m. 210-12°; p-nitroanilino, m. above 300°. 2-p-Ckloroanilino-4-hydroxy-6-phenylpyrimidine, colorless needles, m. 312-13°. Cf. C.A. 40, 5054.6.</p>				
IT	857413-75-3, 4-Pyrimidinol, 2-p-chloroanilino-6-phenyl- (preparation of)				
RN	857413-75-3 CAPLUS				
CN	4-Pyrimidinol, 2-p-chloroanilino-6-phenyl- (5CI) (CA INDEX NAME)				



L4 ANSWER 46 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1948:8847 CAPLUS

DN 42:8847

OREF 42:1971h-i,1972a-c

TI 4-Halo-6-methylpyrimidine derivatives

IN Curd, Francis H. S.; Raison, Clifford G.; Rose, Francis L.

PA Imperial Chemical Industries Ltd.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2433440		19471230	US	


AB The compds. are prepared by heating a 4-hydroxy derivative of 6-methylpyrimidine

(I), e.g. 2-p-chloroanilino-4-hydroxy-6-methylpyrimidine, and a halogenating agent, e.g. POCl₃. The excess POCl₃ is distilled in vacuo, ice and water are mixed in, then NH₃ is added to faint alkalinity with stirring. The solidified product is crystallized from EtOH. The following 2-derivs. of 4-chloro-6-methylpyrimidine are reported: p-chloroanilino, m. 126-7°; p-methoxyanilino, m. 103-5°; (p-ethoxyphenyl), m. 116-18°; p-toluidino, irregular colorless tabular crystals, m. 104-6°; (p-methylmercaptoanilino), m. 81-2°; p-cyanoanilino, m. 215-16°; p-nitroanilino, m. 248-50°; (2-naphthylamino), colorless thick prisms, m. 145-7°; (6-bromo-2-naphthylamino), needles, m. 152-3°; (6-methoxy-2-naphthylamino), m. 148-50°; (2,4-dichloroanilino), m. 120-2°; (3,4-dichloroanilino), m. 134-6°; (3,5-dibromoanilino), m. 131-2°; (2-methyl-4-chloroanilino), m. 107-8°; (3-chloro-4-methylanilino), m. 115-17°; (2,5-dichloroanilino), m. 101°; (3,4-dimethylanilino), m. 128-9°; (3,5-dimethylanilino), m. 86-8°; (4-bromoanilino), m. 140-1°; (4-butylianilino), m. 51-3°; (3-chloroanilino), m. 116-18°; (2-chloroanilino), m. 99-100°; (2-methylanilino), m. 116-18°; (3-methylanilino), m. 101-2°; anilino, colorless needles, m. 92-4°; (2-methoxyanilino), m. 103-4°; (4-dimethylaminoanilino), m. 157-9°; (4-carbomethoxyanilino), m. 223-5°; (4-phenylanilino), m. 124-5°; (1-naphthylamino), m. 131-2°; (4-chloro-1-naphthylamino), m. 170°. 2-(4-Chloroanilino)-4-chloro-6-phenylpyrimidine m. 166-8°. Cf. C.A. 40, 5054.6.

IT 859208-32-5, Pyrimidine, 4-chloro-2-p-chloroanilino-6-phenyl- (preparation of)

RN 859208-32-5 CAPLUS

CN Pyrimidine, 4-chloro-2-p-chloroanilino-6-phenyl- (5CI) (CA INDEX NAME)



L4 ANSWER 47 OF 47 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1946:25718 CAPLUS

DN 40:25718

OREF 40:5062a-i,5063a-f

TI Synthetic antimalarials. VII. 2-Arylamino-4-dialkylaminoalkylaminopyrimidines. Variation of substituents in the 5- and the 6-position

AU Curd, F. H. S.; Richardson, D. N.; Rose, F. L.

CS Imperial Chem. Industries, Ltd., Manchester 9

SO Journal of the Chemical Society (1946) 378-84

CODEN: JCSOA9; ISSN: 0368-1769

DT Journal

LA Unavailable

AB The studies in Parts I and II have been extended to compds. having no substituent in the 6-position, a 6-Ph group, and various substituents in the 5-position (with and without a 6-Me group). An attempt has been made to increase their activity by the synthesis of structures capable not only of riboflavin antagonism but also, possibly, of interference with nucleoside synthesis on the basis of the hypothesis (Part III) that pyrimidine derivs. bearing a substituent in position 5 and an aminoalkylamino group in position 4 might be capable of functioning in this way. 2-p-Chloroanilino-4-hydroxypyrimidine, m. 242-4°, results in 21.5-g. yield from 18 g. 4-hydroxy-2-methylmercaptopyrimidine and 32 g. p-ClC₆H₄NH₂ in 50 cc. EtOCH₂CH₂OH on refluxing 26 h.; 4-Cl derivative, m. 124°. 4-Hydroxy-2-methylmercapto-6-phenylpyrimidine (8.2 g.) and 12 g. p-ClC₆H₄NH₂, heated 6 h. at 130-40°, give 9.7 g. of 2-p-chloroanilino-4-hydroxy-6-phenylpyrimidine, m. 312-13°; 4-Cl derivative, m. 166-8°. 4-Hydroxy-2-(ethylmercapto)-5,6-dimethylpyrimidine (15 g.) and 26 g. p-ClC₆H₄NH₂, heated 9 h. at 130-40°, give 20.85 g. of 2-p-chloroanilino-4-hydroxy-5,6-dimethylpyrimidine, m. 270-2°; 4-Cl derivative, m. 161-2°. 2-p-Chloroanilino-4-hydroxy-6-methyl-5-ethylpyrimidine, m. 246-7°; 4-Cl derivative, m. 128-30°. 2-p-Chloroanilino-4-hydroxy-5-benzyl-6-methylpyrimidine, m. 258-60°; 4-Cl derivative, m. 124-5°. 4-Hydroxy-2-methylmercapto-6-methylpyrimidine (45 g.) and Br in AcOH give 41 g. of the 5-Br derivative, m. 254-6°; 11.75 g. and 12.75 g. p-ClC₆H₄NH₂ in 25 cc. EtOCH₂CH₂OH, heated at 120-30° for 26 h., give 11.75 g. of 5-bromo-2-p-chloroanilino-4-hydroxy-6-methylpyrimidine, m. 267-9° (decomposition); 4-Cl derivative, m. 176-8°. Et cyclohexanone-2-carboxylate (I) (29 g.) and 24 g. S-methylisothiurea sulfate in 150 cc. H₂O containing 12 g. KOH, allowed to stand overnight, give 4.7 g. of 4-hydroxy-2-methylmercapto-5,6-cyclohexenopyrimidine (II), m. 220-2°. I (34 g.) and 16 g. CS(NH₂)₂, added to 12 g. Na in 300 cc. MeOH and the mixture refluxed 5.5 h., give 20.8 g. of 4-hydroxy-2-mercapto-5,6-cyclohexenopyrimidine, m. 314-20° (decomposition); 18.2 g. in 50 cc. 10% KOH, treated with 15 g. Me₂SO₄ in small portions, gives 11.15 g. of II. II (14.8 g.) and 24 g. p-ClC₆H₄NH₂, heated 6 h. at 130-40°, give 19.4 g. of 2-p-chloroanilino-4-hydroxy-5,6-cyclohexenopyrimidine, m. 284-7°; 4-Cl derivative, m. 137-8°. 4-Hydroxy-2-methylmercapto-5,6-cyclopentenopyrimidine, m. 270-2°; 2-p-chloroanilino-4-hydroxy-5,6-cyclopentenopyrimidine, m. 244-6°; 4-Cl derivative, m. 151-2°. 2-p-Chloroanilino-4-hydroxy-5-methylpyrimidine, m. 266-7°; 4-Cl derivative, m. 158-9°. 2-p-Chloroanilino-4-hydroxy-5-phenylpyrimidine, m. 328-30°; 4-Cl derivative, m. 133-4°. 2-p-Anisidino-4-hydroxy-5-phenylpyrimidine, m. 271-2°; 4-Cl derivative, m. 152°. 2-p-Chloroanilino-4-hydroxy-5-phenoxy-5-methylpyrimidine, m. 240-2°; 4-Cl derivative, m. 112-13°. 2-p-Chloroanilino-4-(2-diethylaminoethylamino)pyrimidine (III), m. 71-2°, active at 160°, inactive at 80 mg./kg. (di-HCl salt, with 1.5 mols. H₂O, m.


237-8°); 4-(3-diethylaminopropylamino) homolog, an oil, activity same as III; di-HCl salt, with 2 mols. H₂O, m. 208-10°; dipicrate, m. 218-20°. 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-6-phenylpyrimidine, an oil, questionable activity at 160 mg./kg.; di-HCl salt, m. 277-9°. 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-5,6-dimethylpyrimidine, m. 100-2°, active at 40 mg./kg.; di-HCl salt, with 1 mol. H₂O, m. 270-2°; 4-(3-diethylaminopropylamino) homolog, m. 104-6°, marked activity at 80 mg./kg.; di-HCl salt, with 1 mol. H₂O, m. 277-9° (decomposition); 4-(3-dimethylaminopropylamino) homolog, m. 116-18°, marked activity at 40 mg./kg.; di-HCl salt, with 1 mol. H₂O, m. 238-40°. 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-5-ethyl-6-methylpyrimidine, m. 92-4°, active at 80 mg./kg.; di-HCl salt, with 0.5 mol. H₂O, m. 258-60°; 4-(2-dimethylaminoethylamino) homolog, m. 115-16°, active at 80, inactive at 40 mg./kg.; di-HCl salt, with 1 mol. H₂O, m. 262°; 4-(3-diethylaminopropylamino) homolog, m. 108-9°, active at 80, inactive at 40 mg./kg.; di-HCl salt, with 1 mol. H₂O, m. 272-4°; 4-(3-dimethylaminopropylamino) homolog, m. 126-8°, marked activity at 80 mg./kg.; di-HCl salt, with 1.5 mols. H₂O, m. 244-6°; 4-(4-diethylamino-1-methylbutylamino) homolog, an oil, active at 160, inactive at 120 mg./kg.; di-HCl salt, with 1.5 mols. H₂O, m. 231-3°. 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-5-benzyl-6-methylpyrimidine, m. 114-15°, active at 40 mg./kg.; di-HCl salt, with 0.5 mol. H₂O, m. 255-6°; 4-(3-diethylaminopropylamino) homolog, m. 104-5°, active at 160, inactive at 80 mg./kg.; di-HCl salt, m. 274-6° (decomposition); 4-(3-dimethylaminopropylamino) homolog, m. 112-14°, active at 160 mg./kg.; di-HCl salt, with 1 mol. H₂O, m. 254-6°; 4-(4-diethylamino-1-methylbutylamino) homolog, an oil, ± activity at 160 mg./kg.; di-HCl salt, with 0.5 mol. H₂O, m. 242-4°. 2-p-Chloroanilino-4-(3-diethylaminopropylamino)-5-bromo-6-methylpyrimidine, m. 94-6°, active at 400 mg./kg.; di-HCl salt, with 0.5 mol. H₂O, m. 238-40°. 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-5,6-cyclohexenopyrimidine, m. 132-4°, marked activity at 200, active at 80, inactive at 40 mg./kg.; di-HCl salt, with 2 mols. H₂O, m. 224-6°; 4-(3-diethylaminopropylamino) homolog, m. 138-40°, active at 40 mg./kg.; di-HCl salt, with 1.5 mols. H₂O, m. 202-4°; 4-(3-dimethylaminopropylamino) homolog, m. 125-7°, active at 10 mg./kg.; di-HCl salt, m. 290° (decomposition). 2-p-Chloroanilino-4-(3-dimethylaminopropylamino)-5,6-cyclopentenopyrimidine, m. 142-4°, active at 80 mg./kg. 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-5-methylpyrimidine, m. 106-8°, inactive; di-HCl salt, m. 269° (decomposition). 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-5-phenylpyrimidine, m. 152-3°, ± activity at 160 mg./kg.; di-HCl salt, m. 264-6°; 4-(3-diethylaminopropylamino) homolog, m. 155-6°, inactive; di-HCl salt, m. 264-6°. 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-5-phenoxyypyrimidine, m. 84-5°, ± activity at 160 mg./kg. 2-p-Toluino-4-(2-diethylaminoethylamino) pyrimidine di-HCl, with 1 mol. H₂O, m. 220-1°. 2-p-Anisidino-4-(2-diethylaminoethylamino)-5-phenylpyrimidine, m. 158-9°; di-HCl salt, with 1.5 mols. H₂O, m. 209-11°. Full biol. details will be published and discussed elsewhere.

IT 857413-75-3, 4-Pyrimidol, 2-(p-chloroanilino)-6-phenyl-
 858269-66-6, 4-Pyrimidol, 2-(p-chloroanilino)-5-phenyl-
 859208-32-5, Pyrimidine, 4-chloro-2-(p-chloroanilino)-6-phenyl-
 861032-41-9, Pyrimidine, 2-(p-chloroanilino)-4-(2-diethylaminoethylamino)-6-phenyl-, dihydrochloride 861032-43-1, Pyrimidine, 2-(p-chloroanilino)-4-(2-diethylaminoethylamino)-6-phenyl-

861032-45-3, Pyrimidine, 2-(p-chloroanilino)-4-(2-diethylaminoethylamino)-5-phenyl-, dihydrochloride 861032-47-5, Pyrimidine, 2-(p-chloroanilino)-4-(2-diethylaminoethylamino)-5-phenyl- 861032-61-3, Pyrimidine, 2-(p-chloroanilino)-4-(3-diethylaminopropylamino)-5-phenyl-, dihydrochloride 861032-63-5, Pyrimidine, 2-(p-chloroanilino)-4-(3-diethylaminopropylamino)-5-phenyl- 861032-86-2, Pyrimidine, 4-chloro-2-(p-chloroanilino)-5-phenyl- (preparation of)


RN 857413-75-3 CAPLUS

CN 4-Pyrimidinol, 2-p-chloroanilino-6-phenyl- (5CI) (CA INDEX NAME)




RN 858269-66-6 CAPLUS

CN 4-Pyrimidinol, 2-(p-chloroanilino)-5-phenyl- (4CI) (CA INDEX NAME)




RN 859208-32-5 CAPLUS

CN Pyrimidine, 4-chloro-2-p-chloroanilino-6-phenyl- (5CI) (CA INDEX NAME)




RN 861032-41-9 CAPLUS

CN Pyrimidine, 2-(p-chloroanilino)-4-(2-diethylaminoethylamino)-6-phenyl-, dihydrochloride (4CI) (CA INDEX NAME)




●2 HCl

RN 861032-43-1 CAPLUS
 CN Pyrimidine, 2-(p-chloroanilino)-4-(2-diethylaminoethylamino)-6-phenyl-
 (4CI) (CA INDEX NAME)




RN 861032-45-3 CAPLUS
 CN Pyrimidine, 2-(p-chloroanilino)-4-(2-diethylaminoethylamino)-5-phenyl-,
 dihydrochloride (4CI) (CA INDEX NAME)




●2 HCl

RN 861032-47-5 CAPLUS
 CN Pyrimidine, 2-(p-chloroanilino)-4-(2-diethylaminoethylamino)-5-phenyl-
 (4CI) (CA INDEX NAME)




RN 861032-61-3 CAPLUS
 CN Pyrimidine, 2-(p-chloroanilino)-4-(3-diethylaminopropylamino)-5-phenyl-,
 dihydrochloride (4CI) (CA INDEX NAME)




●2 HCl

RN 861032-63-5 CAPLUS

CN Pyrimidine, 2-(p-chloroanilino)-4-(3-diethylaminopropylamino)-5-phenyl-
(4CI) (CA INDEX NAME)

RN 861032-86-2 CAPLUS

CN Pyrimidine, 4-chloro-2-(p-chloroanilino)-5-phenyl- (4CI) (CA INDEX NAME)



=> => d his

(FILE 'HOME' ENTERED AT 17:10:41 ON 15 NOV 2006)

FILE 'REGISTRY' ENTERED AT 17:10:47 ON 15 NOV 2006

L1 STRUCTURE UPLOADED
 L2 9 S L1 SSS SAM
 L3 378 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:14:01 ON 15 NOV 2006

L4 47 S L3

FILE 'CAOLD' ENTERED AT 17:15:02 ON 15 NOV 2006

=> s l3

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.44	410.44

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-35.25

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:15:14 ON 15 NOV 2006